Skip to main content
PLOS One logoLink to PLOS One
. 2022 Jun 8;17(6):e0269572. doi: 10.1371/journal.pone.0269572

A rapid and sensitive assay for quantifying the activity of both aerobic and anaerobic ribonucleotide reductases acting upon any or all substrates

Talya S Levitz 1, Gisele A Andree 2, Rohan Jonnalagadda 1, Christopher D Dawson 1, Rebekah E Bjork 3, Catherine L Drennan 1,2,3,4,*
Editor: Anna Kristina Croft5
PMCID: PMC9176816  PMID: 35675376

Abstract

Ribonucleotide reductases (RNRs) use radical-based chemistry to catalyze the conversion of all four ribonucleotides to deoxyribonucleotides. The ubiquitous nature of RNRs necessitates multiple RNR classes that differ from each other in terms of the phosphorylation state of the ribonucleotide substrates, oxygen tolerance, and the nature of both the metallocofactor employed and the reducing systems. Although these differences allow RNRs to produce deoxyribonucleotides needed for DNA biosynthesis under a wide range of environmental conditions, they also present a challenge for establishment of a universal activity assay. Additionally, many current RNR assays are limited in that they only follow the conversion of one ribonucleotide substrate at a time, but in the cell, all four ribonucleotides are actively being converted into deoxyribonucleotide products as dictated by the cellular concentrations of allosteric specificity effectors. Here, we present a liquid chromatography with tandem mass spectrometry (LC-MS/MS)-based assay that can determine the activity of both aerobic and anaerobic RNRs on any combination of substrates using any combination of allosteric effectors. We demonstrate that this assay generates activity data similar to past published results with the canonical Escherichia coli aerobic class Ia RNR. We also show that this assay can be used for an anaerobic class III RNR that employs formate as the reductant, i.e. Streptococcus thermophilus RNR. We further show that this class III RNR is allosterically regulated by dATP and ATP. Lastly, we present activity data for the simultaneous reduction of all four ribonucleotide substrates by the E. coli class Ia RNR under various combinations of allosteric specificity effectors. This validated LC-MS/MS assay is higher throughput and more versatile than the historically established radioactive activity and coupled RNR activity assays as well as a number of the published HPLC-based assays. The presented assay will allow for the study of a wide range of RNR enzymes under a wide range of conditions, facilitating the study of previously uncharacterized RNRs.

Introduction

Ribonucleotide reductases (RNRs) use radical-based chemistry to convert ribonucleotides to deoxyribonucleotides, maintaining the cellular deoxyribonucleotide pools that are needed for DNA biosynthesis and repair (Fig 1). RNRs are medically important enzymes; human RNR is a drug target for cancer, and bacterial RNRs have been proposed as antibiotic targets [16]. The ribonucleotide reductase enzyme family is broken broadly into three main classes, named class I, class II, and class III, based upon the cofactor used to generate a catalytically-essential thiyl radical species in the enzyme active site (Fig 1; Table 1) [2, 7, 8].

Fig 1. An overview of the ribonucleotide reductase reaction, classes, and allosteric regulation.

Fig 1

(A) Ribonucleotide reductase catalyzes the conversion of ribonucleotide di- or triphosphates to their corresponding deoxyribonucleotide via a catalytic cysteine radical. (B) Examples of class I, class II, and class III enzymes with their corresponding metallocofactors and radical harbors. In each structure, one specificity effector site is circled in green and one substrate site is circled in magenta. The E. coli class Ia RNR (left) is shown in the active form with the catalytic subunits (NrdA) shown in blue and the radical-generating subunits (NrdB) shown in orange/red (PDB 6W4X) [52]. Bound nucleotides (GDP substrate and TTP specificity effector) are shown as spheres. The activity effector site, which does not have any bound nucleotide in this structure, is circled in orange. The diiron-oxo center and tyrosyl radical shown below the structure are found in the radical-generating subunit and are specific to class Ia RNRs; see Table 1 for the radical harbors of other subclasses of class I RNRs. The Thermotoga maritima class II RNR (NrdJ; middle) is shown with the bound nucleotides (GDP substrate and TTP specificity effector) shown as spheres (PDB 3O0O) [34]. The S-adenosylcobalamin (B12) cofactor found in each subunit is shown as sticks and is highlighted below the structure. The Escherichia coli T4 bacteriophage class III RNR (NrdD; right) is shown with bound nucleotides (dGTP) shown as spheres (PDB 1HK8) [85]. The activase NrdG is structurally uncharacterized and contains the 4Fe-4S cluster shown below the structure. NrdG in complex with S-adenosylmethionine generates a glycyl radical is generated on the catalytic subunit via a transient interaction. (C) Allosteric regulation of RNRs that use NDPs (left) or NTPs (right) as substrates. Following reduction of nucleotides, the deoxyribonucleotide products are either first converted to dNTPs (left) or directly used (right) as specificity effectors for determining which nucleotides bind the active site for future reduction reactions (blue arrows). In some but not all RNRs, ATP acts as an overall positive activity effector and dATP at high concentrations acts as an overall negative activity effector; ATP can also act as a specificity effector in vitro and possibility in vivo. Figure modified from [78].

Table 1. Comparison of class I, class II, and class III RNRs highlighting the differences that make a universal activity assay challenging.

Subclasses of class III RNRs are listed as NrdD1, NrdD2, and NrdD3.

Class I Class II Class III
Oxygen requirement Aerobic Oxygen-independent Anaerobic
Subunits Required for Activity Catalytic subunit and radical-storage subunit Single subunit Catalytic subunit and activase (activase required for installation of glycyl radical species G•)
Radical harbor Tyr• (class Ia and Ib)
Unpaired electron in metal center (class Ic and Id)
DOPA• in presence of NrdI (class Ie)
5’-adenosylcobalamin (B12) S-adenosyl methionine/[4Fe-4S]/ G•
Substrate NDPs NDPs or NTPs NTPs
Reducing system Thioredoxin, thioredoxin reductase, and NADPH
Or
Glutaredoxin, glutathione, glutathione reductase, and NADPH
Thioredoxin, thioredoxin reductase, and NADPH Formate (NrdD1)
Thioredoxin (NrdD2)
Glutaredoxin-like NrdH (NrdD3)

Class Ia enzymes, whose membership includes both the canonical E. coli class Ia RNR (EcRNR) and human RNR, are obligately aerobic enzymes that use a di-iron tyrosyl radical cofactor, housed in a β2 subunit, to generate the thiyl radical species in the active site of the catalytic (α2) subunit (Fig 1; Table 1) [2, 9, 10]. Despite having been studied for the past sixty years, new subclasses of class I RNRs are still being discovered, demonstrating the diversity and unknown potential even within classes of RNRs [1114]. Class II RNRs are oxygen-independent enzymes that use 5′-adenosylcobalamin to generate the catalytically-essential thiyl radical species [15, 16]. In contrast to class I RNRs, which only act on ribonucleoside diphosphate (NDP) substrates, class II RNRs are divided in whether they act on ribonucleoside triphosphate (NTP) substrates or NDP substrates [1724]. Lastly, the class III RNRs are obligately anaerobic enzymes due to the presence of a post-translationally installed glycyl radical cofactor that is oxygen-sensitive [2527]. Unlike class I and class II enzymes that typically use a reducing system comprised of thioredoxin (Trx), thioredoxin reductase (TrxR) and nicotinamide adenine dinucleotide phosphate (NADPH), most characterized class III RNRs (NrdDs) are of the NrdD1 subclass, which use formate as the reductant, although there are two other NrdD subclasses that use different reductants (Table 1) [2, 8, 28].

RNRs are tightly regulated in order to keep cellular ribonucleotide and deoxyribonucleotide pools balanced; disruption of these nucleotide pools via disruption of RNR activity or RNR regulation can have disastrous consequences for the cell [2933]. In addition to the substrate binding site, each RNR catalytic subunit contains either one or two allosteric nucleotide binding sites (Fig 1). The first site, present in all RNRs, is known as the specificity site and structurally informs which of the four ribonucleotide substrates is preferred in the active site [7, 9, 34, 35]. Although all classes of RNRs contain a specificity site, how the nucleotide in the specificity site determines what nucleotide is bound in the active site has not been fully investigated outside of the prototypical class Ia EcRNR and a few other RNRs [3439]. The second site, termed the activity site, is only present in RNRs containing a conserved N-terminal cone domain [40, 41]. In RNRs containing this cone domain, the activity site acts as an on/off switch for the enzyme: binding dATP inactivates the enzyme, whereas displacement of dATP by ATP reactivates the enzyme [2, 4143]. Approximately 47% of class I RNRs and 7% of class II RNRs contain a cone domain, although not all RNRs that contain a cone domain have activity regulation and at least one RNR without a full cone domain has exhibited activity regulation [4447]. Unfortunately, although 76% of the known class III RNRs contain one or multiple cone domains, neither of the two published structures of class III RNRs are RNRs that have a cone domain [34, 46, 48]. Much is still unknown about the structural and biochemical basis of activity regulation, if present, in RNRs that are not class Ia RNRs.

The development of a universal RNR activity assay has been a longtime goal that has been complicated by all of the factors mentioned above: two different substrate phosphorylation states, differences in reducing systems used, presence/absence of allosteric activity regulation, complex allosteric specificity relationships, and oxygen requirements among and between the class I, class II, and class III RNRs (Table 1). The main activity assay that has historically been used to measure RNR activity is a radioactivity-based assay [10, 4951]. In this assay, RNR converts radioactive substrate (generally tritiated CDP or CTP) to radioactive product (tritiated dCDP or dCTP). At each time point in the reaction, the reaction is stopped either chemically or via heat before product is separated from the remaining substrate through the use of a boronate affinity column that selectively binds the 2′ and 3′ hydroxyl groups of the substrate’s ribose. The flow-through from the column, which contains only radioactive deoxyribonucleotide product, is then quantified for radioactivity using a liquid scintillation counter. Although this radioactive assay is well established in the field, it has numerous drawbacks, including generally only being performed on CDP as opposed to other substrates due to the need for HPLC separation for GDP reduction and expense/availability of radiolabeled UDP and ADP [52]. Additionally, the radioactive assay can only measure reduction of a single ribonucleotide species at one time, despite the enzyme reducing all four ribonucleotide substrates simultaneously in vivo. The use of radioactive substrates also requires special training, dedicated space, and radioactivity licenses, and can be particularly challenging for class III RNRs, which must be assayed in anaerobic chambers that are often not certified for radioactivity.

A second historically-utilized assay in the RNR field is a coupled assay that measures the spectrophotometric change when NADPH is oxidized to NADP+ [53, 54]. This assay does not directly measure products, and so it only works for RNRs that use an NADPH/Trx /TrxR reducing system, notably excluding the class III RNRs that use formate as the reductant. Additionally, the assay requires the cloning and purification of the Trx and TrxR proteins that correspond to each ribonucleotide reductase being measured; these enzymes may be difficult to procure or express, such as in the example of the human TrxR, which contains a selenocysteine residue [55, 56]. The coupled assay often displays large variability between replicates and, similarly to the radioactivity assay, can only be used to measure reduction of one single substrate/effector pair at a time.

In light of the above concerns for the most historically-established assays, numerous groups have turned to HPLC-based assays to separate and detect effectors, substrates, and products. As early as the 1980s, an HPLC protocol was published that separated substrate from product but required radioactivity to detect product traces [52, 57]. Subsequent protocols utilizing HPLC-based detection of products have been generated that do not need radioactivity, greatly increasing the access of researchers to measure product formation of various RNRs [11, 21, 22, 44, 5863]. These assays have been effectively used to measure the absolute or relative activities of a wide variety of RNRs from numerous classes, including in one case under anaerobic conditions [62] and, in multiple other cases, measuring the reduction of all four substrates simultaneously [21, 59, 60]. However, many of these assays are still hampered by long run times (40–180 minutes) and/or relatively high flow rates (1–1.5 mL/min), which makes the analysis of many samples a time- and reagent-consuming process [44, 58, 60, 61]. Additionally, in order to get enough product to see each peak on the HPLC trace, some assays are completed over a longer period of time (15–60 mins) [11, 21, 22, 44, 5861, 63], and assay speed is not just a matter of convenience: RNRs have radical cofactors with various degrees of stability necessitating an assay speed faster than radical cofactor decay. Part of the reason that the class Ia EcRNR is the workhorse of the RNR family is that it has a tyrosyl radical that is relatively stable (lifetime of several days) [64]. To study RNRs with less stable radical cofactors (e.g., the half-life of the Y• of the mouse β2 is 10 minutes), assay speed is an important consideration [65]. Lastly, due to the focus on the biological questions at hand and the study of RNRs from diverse organisms in the above references, there is no published method validation or comparisons of activities generated using the HPLC-based assays to established values in the field.

With the many assays present in the literature in mind, we set out to generate and validate an assay that could measure reduction of all four ribonucleotides simultaneously from any class of RNR. An LC-MS/MS-based assay was chosen for its ability to easily differentiate and directly measure the four deoxyribonucleotide products from a mixture of substrate and products. Here, we describe an assay that (1) uses unlabeled substrates, a low flow rate, and short run times; (2) differentiates all four deoxyribonucleotide products from one another; and (3) can be done either in an anaerobic chamber or on the benchtop, making the assaying of class III RNRs more amenable.

Results

An LC-MS/MS-based assay can determine the activity of ribonucleotide reductase enzymes

We developed an assay that can be used to measure the activity of both aerobic and anaerobic ribonucleotide reductase enzymes (Fig 2). In the assay (final volume 240–250 μL), mastermixes consisting of the α2 subunit of EcRNR (NrdA; final concentration 0.1 or 0.5 μM), nucleotides (variable concentrations), Trx (final concentration 30 μM), TrxR (final concentration 0.5 μM), and NADPH (final concentration 200 μM) or of activated class III RNR from Streptococcus thermophilus (StNrdD; final concentration 0.1 μM), nucleotides (variable concentrations) and formate (final concentration 12.5 mM) are generated and allowed to equilibrate at 37°C. For all assays described below, the RNR subunit being assayed was held as the limiting reagent at 0.1 μM with nucleotide concentrations varied based on experimental question; optimization of concentration will be necessary for RNRs not presented here to determine what concentrations yield measurable activity within the linear range of the assay.

Fig 2. Overall scheme of LC-MS/MS RNR activity assay.

Fig 2

Either aerobically or anaerobically, a mastermix is created and a zero point is taken prior to initiation with beta (aerobic assays) or nucleotides (anaerobic assays). The reaction is allowed to proceed for 120 s with time points taken every 30 s. Inactivation of the reaction occurs by heating the sample to 95°C in a thermocycler or heat block. After inactivation, anaerobic assays are removed from the box and all assays have 1 μL of calf intestinal phosphatase (CIP) added to dephosphorylate the nucleotides at 37°C for 2 hours. The samples are then filtered through a 0.2 μm filter and transferred to mass spectrometry vials for analysis via LC-MS/MS.

A zero point is taken prior to initiation, and then the remaining mastermix is initiated with a small amount (generally 1–5 μL, concentration-dependent) of either β2 (NrdB for EcRNR; final concentration 0.5 or 0.1 μM) for class Ia RNRs or nucleotides (variable concentrations) for class III RNRs and mixed via pipetting while being held at 37°C. The reaction proceeds at 37°C with time points taken every 30 seconds for 120 seconds. At each time point, a 40 μL aliquot of the reaction is inactivated by rapid heating to 95°C. We confirmed that the thermophilic StNrdD is completely inactivated at 95°C; the melting temperature of the enzyme was determined to be approximately 50°C in the presence of nucleotides, which is reached in under 5 seconds after transferring to the 95°C thermocycler (S1 Fig, S1 Table). Following the heat step, all nucleotides are dephosphorylated with the addition of calf intestinal phosphatase (CIP) prior to filtration and transfer to mass spectrometry vials. The CIP dephosphorylation step was optimized (S2 Fig).

Activity is determined by extracting multiple reaction monitoring (MRM) curves for each product from the overall total ion chromatogram (TIC) for each LC-MS/MS run (Fig 3). MRM mode on the mass spectrometer filters the total incoming ions, which are used to generate the TIC, by the individual parent and fragmented ion masses for each product, allowing for the generation of a separate curve for each product and deconvolution of overlapping peaks in the TIC, and ensuring the measured signal is due solely to the product of interest. Slight run-to-run variability in retention time (on the order of maximum ± 0.3 mins) is occasionally seen for some products, but retention time is not used as the primary determinant of product identity due to the precision of the MRM mode in isolating each product signal by mass and fragmentation pattern (Fig 3, S2 Table).

Fig 3. Measurement of RNR activity for a single nucleotide under a single condition.

Fig 3

(A) Generation of a dC standard curve. A multiple reaction monitoring (MRM) curve for dC (m/z 228.2 > 112.1) is extracted from the initial total ion chromatogram (TIC) and the peaks are integrated (all in triplicate; one set of standards is shown above for the TIC and MRM) to generate a standard curve that relates the area under the dC MRM peak to the nmoles dC injected. The peak in the TIC at approximately 1.4 mins corresponds to the desired dephosphorylated product (dC) whereas the peak at approximately 3.5 mins corresponds to the dephosphorylated effector (A) in this experiment; note the MRM peak for dC is at the same retention time as the dC peak in the TIC. (B) Calculation of sample activity. Another set of MRM curves are extracted and integrated from TICs for each of the time points of the assay. The integrated MRM values are then converted to nmol dC / mg NrdA by using the standard curve to calculate nmol dC injected and then dividing by the mg NrdA in each injection. The slope of the line (in nmol/mg-min; after the aforementioned has been completed in triplicate) is the activity of the protein. All reactions are done in triplicate and are shown as mean ± standard error of the mean. The above condition contained NrdA (0.1 μM dimer), NrdB (0.5 μM dimer), ATP (3000 μM), CDP (1000 μM), Trx (30 μM), TrxR (0.5 μM), and NADPH (200 μM).

To calculate activity, a standard curve is first generated by plotting the area under the curve of the MRM signals against known concentration for each standard (Fig 3A). It is imperative that the standards do not only contain the desired deoxyribonucleoside(s) but also contain the same concentrations of substrates, effectors, and phosphates as the samples in order for standard curves to accurately reflect product concentration; the other components can affect ionization and thus detection of the deoxyribonucleoside standards in the mass spectrometer (S3 Fig). The areas under the curve of the MRM signals for the assay samples are then converted into quantity of product generated at each time point by using the standard curve (Fig 3B). The calculated product generated at each time point is graphed (in triplicate), and the slope of the resulting line (in nmol product/min) is used in conjunction with the mass of the limiting subunit of RNR (if applicable) to determine the reported activity in nmol product/mg-min.

E. coli class Ia RNR activity assay results are similar to established activities

EcRNR activities were measured using the LC-MS/MS assay under conditions found in the literature using the established radioactive and coupled assays. The activity of NrdA in the presence of 5x NrdB, 1 mM substrate CDP, and 3 mM allosteric activator ATP was found to be 2880 ± 30 nmol dCDP/mg-min, whereas the activity of NrdB in the presence of 5x NrdA under the same nucleotide conditions was found to be 10000 ± 1000 nmol dCDP/mg-min (Fig 4). These data are in comparison to published values of 1500–3800 and 5000–8000 nmol dCDP/mg-min, respectively, using established (radioactivity and coupled) assays under the same nucleotide conditions [35, 51, 53, 54, 6668]. In contrast, the activity of NrdA in the presence of 5x NrdB, 1 mM substrate CDP, and 0.175 μM allosteric inhibitor dATP was found to be 19 ± 1 nmol dCDP/mg-min, indicating 99% inactivation of NrdA by dATP (Fig 4). This activity is in comparison to published values of 175–300 nmol dCDP/mg-min using established assays under the same nucleotide conditions [35, 53]; similar studies on dATP inhibition of wild-type E. coli NrdA indicate that the addition of a similar concentration (100 μM) of dATP inhibits between 80% and >95% of enzyme activity as compared to activity in the presence of activating (~1 μM) concentrations of dATP and 0.5 mM CDP substrate [58, 69].

Fig 4. Activity of E. coli class Ia ribonucleotide reductase.

Fig 4

Each bar represents average activity +/- standard error of the mean for three replicates. NrdA ATP and dATP conditions had 0.1 μM NrdA and 0.5 μM NrdB and 3000 μM ATP or 0.175 μM dATP, respectively, whereas the NrdB condition had 3000 μM ATP, 0.1 μM NrdB, and 0.5 μM NrdA. All conditions contained CDP (1000 μM), Trx (30 μM), TrxR (0.5 μM), and NADPH (200 μM). All protein concentrations are expressed as concentration of the dimer.

Anaerobic (class III) RNR activity can be measured using the LC-MS/MS assay

The activity of the class III RNR from S. thermophilus, StNrdD, in the presence of 1 mM substrate GTP, 1 mM allosteric specificity effector TTP, and no allosteric activity effector was observed to be 110 ± 15 nmol dGTP/mg-min. In the presence of 3 mM allosteric activator ATP, 1 mM each GTP and TTP, activity was raised to 950 ± 70 nmol dGTP/mg-min. Activity was lowered to 3.9 ± 0.5 nmol dGTP/mg-min in the condition of 3 mM allosteric inhibitor dATP, 1 mM GTP, and 1 mM TTP (Fig 5). There are no previous determinations of StNrdD activity, but the activity of the class III RNR from Lactococcus lactis has been measured to be 800–1000 nmol dCTP produced/mg-min in the presence of 1.5 mM ATP and 0.2 mM dCTP; addition of dATP reduced activity to approximately 50 nmol dCTP/mg-min [39]. The T4 bacteriophage class III RNR, which does not exhibit activity regulation, has reported activities of 575 nmol dCTP produced/mg-min in the presence of 1.5 mM CTP and 1 mM ATP, 730 nmol/mg-min in the presence of 1.5 mM CTP and 1 mM dATP, and 370 nmol/mg-min in the presence of 1.5 mM CTP and no effector [36]. Other, much lower, activities have been reported in the literature for additional class III RNRs (10 ± 1, 49, and 55 ± 3 nmol dCTP produced/mg-min for class III RNRs from Thermotoga maritima, Neisseria bacilliformis, and Methanosarcina barkeri, respectively); however, these activities may increase with further optimization of fully anaerobic conditions, glycyl radical installation, and/or necessary assay components [28, 48, 70].

Fig 5. Activity of StNrdD class III ribonucleotide reductase enzyme.

Fig 5

(A) Activity assay data for ATP, dATP, and no allosteric activity effector in the presence of GTP (substrate) and TTP (specificity effector). Error bars are shown for all replicates (3 replicates per data point) but are too small to visualize for some conditions. (B) Activities calculated from assay data in (A). Each bar represents average activity +/- standard error of the mean for three replicates. All conditions contained 0.10 μM StNrdD with 1.5 ± 0.10 glycyl radicals/dimer, 1 mM substrate GTP, 1 mM specificity effector TTP, 5 mM DTT, and 12.5 mM sodium formate; the ATP condition contained 3 mM allosteric activator ATP whereas the dATP condition contained 3 mM allosteric inhibitor dATP.

An internal standard eliminates the need for same-day standard curves

All standard curves associated with data presented above were run on the same day as their associated samples due to day-to-day variability in the mass spectrometer. However, the need for same-day standard curves can be avoided with the addition of internal standards into both the standard curves and the assay samples (Fig 6). Addition of 1 μL of 1.6 mM heavy (13C/15N) dCTP to each sample and standard tube in a CDP reduction assay (leading to 0.4 nmoles heavy dC injected per assay), after the 95°C inactivation but prior to the addition of CIP, yields an internal standard peak for each sample and standard that can be used to eliminate day-to-day variability in the dC MRM peak integration value without significantly increasing the cost of the assay. The addition of a single heavy nucleotide as an internal standard adds approximately 25–50 cents per triplicate 5-timepoint assay. Despite two very different standard curves from the same dC standards that were generated over two different days due to instrument variability (Fig 6A), division of each day’s dC MRM integration by the integration of the heavy internal standard led to two almost identical standard curves (Fig 6B). When used to calculate nmoles dC generated in two different activity assays (one with EcNrdA as the limiting protein and one with EcNrdB as the limiting protein), the corrected standard curves yielded almost identical activity curves (Fig 6C). These activity curves led to indistinguishable calculations of final activity for EcNrdA (2000 ± 300 vs. 2200 ± 400 nmoles dC/mg-min) and EcNrdB (8000 ± 600 nmoles dC/mg-min vs. 9000 ± 700 nmoles dC/mg-min).

Fig 6. The use of internal standards eliminates the need for same-day standard curves.

Fig 6

(A) Standard curves of the same amount of dC (0–1 nmole) run on the mass spectrometer on two different days (day 1 and day 2). (B) Standard curves run on day 1 and day 2 after internal standard correction (the area under the MRM curve of the heavy [13C/15N] dC nucleoside). (C) Activity assay data for EcNrdA and EcNrdB with nmoles dC calculated after correction of both standard and sample dC integration using a heavy dC internal standard. Both assays were run on day 2 along with the day 2 standard curve used for day 2 activity calculation; day 1 standard curve used for day 1 activity calculation was run on a previous day. (D) Calculation of activity from curves in (C) with EcNrdA or EcNrdB as the limiting reagent. NrdA activity was determined to be 2000 ± 300 nmoles dC/mg-min using the day 2 standard curve to calculate activity and 2200 ± 400 nmoles dC/mg-min using the day 1 standard curve to calculate activity. NrdB activity was determined to be 8000 ± 600 nmoles dC/mg-min using the day 2 standard curve to calculate activity and 9000 ± 700 nmoles dC/mg-min using the day 1 standard curve to calculate activity. The above conditions contained NrdA (0.1 μM dimer for NrdA condition and 0.5 μM dimer for NrdB condition), NrdB (0.5 μM dimer for NrdA condition and 0.1 μM dimer for NrdB condition), ATP (3000 μM), CDP (1000 μM), Trx (30 μM), TrxR (0.5 μM), and NADPH (200 μM).

All four ribonucleotide substrates can be assayed simultaneously using the LC-MS/MS assay

In addition to assaying the production of a single deoxyribonucleotide product, the production of all four deoxyribonucleotide products (dADP, dCDP, dGDP, and dUDP for class I RNRs) can be simultaneously measured using the LC-MS/MS assay (Fig 7; S4 Fig). The total ion chromatogram (TIC) containing all four deoxyribonucleoside traces can be deconvoluted using multiple reaction monitoring (MRM) for each of the four deoxyribonucleoside products to generate four separate activity assay curves (Fig 7; S4 Fig).

Fig 7. Activity of E. coli class Ia ribonucleotide reductase reducing all four ribonucleotides simultaneously in the presence of specificity effectors dATP, dGTP, and TTP and activity effector ATP.

Fig 7

(A) Standard curves of all four ribonucleotides mixed together in concentrations of 0–100 μM (10 μL injections). (B) Activity graphs of all four ribonucleotide products being produced simultaneously over two minutes. (C) Bar graph showing production of each of the four deoxyribonucleotide products. The dU activity above condition contained Trx (30 μM), TrxR (0.5 μM), NADPH (200 μM), ATP (3000 μM), dATP (500 μM), TTP (250 μM), dGTP (100 μM), CDP (70 μM), UDP (50 μM), GDP (200 μM), ADP (110 μM), NrdA (0.1 μM dimer), and NrdB (0.5 μM dimer). Total ion chromatogram (TIC) and individual multiple reaction monitoring (MRM) curves are shown in S4 Fig.

We determined the activity of E. coli NrdA on all four ribonucleotide substrates in the presence of approximately physiological concentrations of substrate and effector nucleotides with varying concentrations (0–1 mM) of each specificity effector (Fig 8, Table 2) [71, 72]. Our estimates of physiological nucleotide concentrations were based on measurements made by Buckstein and colleagues in mid-log growth for E. coli: ATP (3560 μM), dATP (181 μM), dGTP (54 μM), TTP (256 μM), ADP (116 μM), GDP (203 μM), UDP (54 μM) [72]; these concentrations also closely match previously-published values [73]. We also considered Traut et al. values for non-human organisms, especially for CDP concentrations which were not measured in the studies listed above: ATP (3000 ± 2000 μM), dATP (20 ± 20 μM); dGTP (5 ± 4 μM), TTP (40 ± 30 μM), ADP (800 ± 400 μM), CDP (70 ± 50 μM), GDP (160 ± 50 μM), UDP (200 ± 100 μM) [71].

Fig 8. Assay data with class Ia E. coli ribonucleotide reductase measuring the reduction of all four ribonucleotide substrates simultaneously.

Fig 8

(A) Activity of EcNrdA in the presence of substrates, effectors, and varying amounts of dATP. (B) Activity of EcNrdA in the presence of substrates, effectors, and varying amounts of dGTP. (C) Activity of EcNrdA in the presence of substrates, effectors, and varying amounts of TTP. Each bar is representative of the average activity +/- standard error of the mean for three replicates. The values of each bar are shown in Table 2. Except for the indicated concentrations of allosteric effectors on the X-axis, components and concentrations were as follows: Trx (30 μM), TrxR (0.5 μM), NADPH (200 μM), CDP (70 μM), UDP (50 μM), GDP (200 μM), ADP (110 μM), NrdA (0.1 μM dimer), NrdB (0.5 μM dimer).

Table 2. Average activities +/- standard error of the mean of assays graphically represented in Fig 8.

In addition to the indicated concentration of the allosteric effectors shown below in column 1, components and concentrations were as follows: Trx (30 μM), TrxR (0.5 μM), NADPH (200 μM), CDP (70 μM), UDP (50 μM), GDP (200 μM), ADP (110 μM), NrdA (0.1 μM dimer), NrdB (0.5 μM dimer).

Allosteric effectors Concentration of variable effector dCDP production (nmol/mg-min) dUDP production (nmol/mg-min) dADP production (nmol/mg-min) dGDP production (nmol/mg-min) Overall activity (nmol/mg-min)
Variable dATP 0 mM 70 ± 10 41 ± 4 1300 ± 100 670 ± 80 2100 ± 100
3000 μM ATP 200 μM 890 ± 70 390 ± 20 550 ± 50 550 ± 20 2380 ± 90
100 μM dGTP 500 μM 700 ± 200 350 ± 50 120 ± 10 200 ± 20 1400 ± 300
250 μM TTP 1000 μM 600 ± 100 260 ± 1 28 ± 9 60 ± 20 1000 ± 100
Variable dGTP 0 mM 440 ± 40 270 ± 10 780 ± 80 1080 ± 90 2600 ± 100
3000 μM ATP 200 μM 50 ± 100 94 ± 9 1200 ± 100 290 ± 30 1600 ± 100
20 μM dATP 500 μM 30 ± 10 50 ± 20 1100 ± 300 1000 ± 300 2200 ± 400
250 μM TTP 1000 μM 60 ± 10 31 ± 4 1100 ± 100 80 ±10 1300 ± 100
Variable TTP 0 mM 280 ± 40 130 ± 10 1700 ± 200 130 ± 40 2200 ± 200
3000 μM ATP 200 μM 210 ± 50 110 ± 10 1280 ± 30 580 ± 30 2180 ± 70
20 μM dATP 500 μM 64 ± 9 45 ± 4 700 ± 100 400 ± 70 1200 ± 100
100 μM dGTP 1000 μM 20 ± 10 19 ± 8 300 ± 100 200 ± 100 600 ± 100

We first investigated dATP (physiological concentrations in mid-log phase E. coli reported of 24, 175, and 181 μM [7173]) as the variable effector. dATP is known to be an allosteric specificity effector for CDP and UDP at lower concentrations and an allosteric inhibitor at higher concentrations (see Fig 1C). We found that increasing the amount of dATP from 0 to 200 μM, raising it closer to physiological levels, in the presence of 3000 μM ATP, 100 μM dGTP, and 250 μM TTP raised the overall activity of the enzyme on the ribonucleotide pool (CDP [70 μM], UDP [50 μM], GDP [200 μM], ADP [110 μM]) from 2100 ± 100 to 2380 ± 90 nmol nucleotides reduced/mg-min (Fig 8A, Table 2). This overall modest activity increase is due to large increases in dCDP and dUDP production offset by a large decrease in dADP production and a modest decrease in dGDP production (Fig 8, Table 2). Notably, at 0 mM dATP and approximately physiological concentrations of other effectors, dCDP and dUDP production comprised only 5% of the total enzyme activity, whereas that percentage increased to 54% at 200 μM dATP and increased further to 75% at 500 μM dATP and 86% at 1 mM dATP (Fig 8A, Table 2). Despite the percentage increase for dCDP and dUDP compared to dADP and dGDP with the increase in dATP concentrations from 200 μM to 500 μM and then to 1 mM, enzyme activity on all four ribonucleotide substrates, including CDP and UDP, decreases with increasing concentrations of dATP past average reported physiological levels (Fig 8A, Table 2). Instead of a total enzyme activity of 2380 ± 90 nmol nucleotides reduced/mg-min at 200 μM dATP, at 1 mM dATP, the overall activity is 1400 ± 300 nmol nucleotides reduced/mg-min (Fig 8A, Table 2).

Using the LC-MS/MS assay, we were also able to investigate the degree to which higher concentrations of dATP are needed to inhibit E. coli NrdA’s activity on CDP when other effectors are in the mixture. In particular, NrdA’s activity on CDP with dATP alone (175 μM dATP and 1 mM CDP) is almost nonexistent (Fig 4) compared to an activity value of 890 ± 70 nmol nucleotides reduced/mg-min with 200 μM dATP in the presence of approximately physiological concentrations of ATP (3000 μM) and substrates and other specificity and activity effectors (70 μM CDP, 50 μM UDP, 200 μM GDP, 110 μM ADP, 100 μM dGTP, and 250 μM TTP) (Fig 8A, Table 2). Although we expected ATP to counter the inhibitory effect of dATP, using this assay we can quantitate the effect of ATP/dATP ratios on RNR activity.

When dGTP (physiological concentrations in mid-log phase E. coli reported of 5, 92, and 122 μM [7173]) is the variable specificity effector, an increase from 0 to 200 μM in dGTP in the presence of 3000 μM ATP, 20 μM dATP and 250 μM TTP results in an increase in dADP production and a decrease in dCDP, dUDP, and dGDP production, as expected (see Fig 1C). Enzyme activity on substrate ADP levels off above 200 μM dGTP as levels of dGTP increase further from physiological levels, but the percentage of dADP made compared to dCDP, dUDP, and dGDP is highest at the highest concentration of dGTP (1 mM) (Fig 8, Table 2). When TTP (physiological concentrations in mid-log phase E. coli reported of 37, 256, and 77 μM [7173]) is the variable specificity effector, an increase from 0 to 200 μM in TTP in the presence of 3000 μM ATP, 20 μM dATP and 100 μM dGTP results in an increase in dGDP production and modest decreases in dCDP, dUDP, and dADP production (Fig 8, Table 2). Again, these results are consistent with the specificity rules as shown in Fig 1C. Enzyme activity on substrate GDP reaches a maximum at the approximately physiological concentration of 200 μM TTP (580 +/- 30 nmol/mg-min) and then begins to decrease (Fig 8, Table 2).

In general, increasing amounts of any of the effectors to a supraphysiological (1 mM) concentration dampened overall activity of the enzyme, with the enzyme displaying 48%, 50%, and 27% of its initial (0 mM effector) activity when dATP, dGTP, or TTP, respectively, were raised to a 1 mM concentration (Fig 8, Table 2).

Discussion

The ribonucleotide reductase field has been challenged by a lack of accessible and validated assays that are flexible enough to be used to measure activity of all classes of RNRs. The assay presented here does not have the safety considerations of the radioactive assay and is more flexible in the substrates and reducing systems, and thus increases the classes of RNRs that can be assayed relative to the radioactivity or coupled assays (Table 3). It is also versatile in that various ratios of NrdA:NrdB (for class I RNRs), different substrates/effectors or combinations of substrates/effectors, and different temperatures can be assayed. Additionally, the assay is higher throughput than some existing assays in that many LC-MS vials can be prepared over the course of days and then run with short run times using an autosampler, allowing for activity under many conditions to be determined in a short amount of time. The assay presented here improves on existing HPLC-based assays through the use of short run times, a lack of need to fully deconvolute or identify overlapping or contaminant peaks in the HPLC due to the use of mass spectrometry MRM for specific product parent and fragment ion peaks, and by being thoroughly validated using known proteins and their associated activities prior to moving on to examination of novel RNRs.

Table 3. Comparison of the radioactivity and coupled RNR activity assays and the LC-MS/MS assay described in this paper.

Radioactivity Assay Coupled Assay LC-MS/MS Assay
Safety Considerations Radioactivity license needed None None
Substrates CDP or CTP primarily Any Any
Reducing Systems Accommodated Any NADPH only Any
Classes of RNRs Assayable Any Class I and II, theoretically some class III Any
Multiple Substrates Assayable Simultaneously? No No Yes
Equipment Required Scintillation Counter UV-Vis Spectrophotometer QQQ Mass Spectrometer

E. coli class Ia RNR (NrdA/NrdB) is the most well studied RNR and has been characterized since the early 1960s [9, 10, 42]. Thus, for the purposes of validation, there is a large body of work determining protein activities that can be compared to the activities found using the assay presented here. Although activities can vary slightly due to radical content, protein purity, the method of determining protein concentration, and age of the protein being assayed among other properties and protocols, the activities of both E. coli NrdA and NrdB as determined by the current assay under ATP and dATP conditions closely match those reported in the literature [35, 51, 53, 54, 6668]. The agreement between the activity numbers measured with this assay and the past literature numbers serves to support the validity of this assay. We note that the E. coli proteins studied here are all N-terminally His-tagged, which for NrdA and NrdB has been previously shown to not interfere with activity [74]; however, for characterization of new RNRs we recommend determining activity with and without a tag to ensure the tag is not interfering in protein activity. The Trx and TrxR used here are also His-tagged. To mitigate any decrease in activity, we used a 60x fold excess of Trx in our assays to ensure re-reduction was not the limiting step in any activity assay.

In comparison to the commonly studied E. coli class Ia RNR, there are numerous RNRs that are un- or under-characterized due to the conditions under which they function. This understudied group includes the class III RNRs, which must be studied under anaerobic conditions due to their use of a highly oxygen-sensitive glycyl radical. Additionally, many class III RNRs use formate, not NADPH, as a terminal electron acceptor, making the coupled assay impossible [75]. The radioactivity assay also proves difficult for class III RNRs due to the requirements for an anaerobic chamber that can accommodate radioactive samples and the inherent challenges of performing an assay in an anaerobic environment. Furthermore, class III RNRs have NTPs as both substrates and effectors, as opposed to the NDP substrates and NTP effectors of the well-studied class I enzymes. This dual use of NTPs can create challenges in the separation of effectors and products in some assays. The LC-MS/MS-based assay described here overcomes the above challenges and allows for the determination of activity of any class III RNRs as long as the lab is equipped with an anaerobic chamber. Here we use this LC-MS/MS-based assay to show that the StNrdD, a class III RNR that is expected by sequence to have allosteric activity regulatory or cone domains, is in fact allosterically regulated by ATP and dATP and displays activity on an order of magnitude similar to what has been shown with other class III RNRs [36, 39]. ATP enhances activity and dATP inhibits this class III enzyme. To the best of our knowledge, this is only the third time that a class III RNR has been shown experimentally to be allosterically regulated by ATP and dATP. Previously, the class III RNRs from E. coli and Lactococcus lactis, both of which contain cone domains, have been observed to be under allosteric activity enhancement by ATP and inhibition by dATP [39, 76].

A distinct advantage of the presented assay over the assays currently available to the RNR field is that the LC-MS/MS assay is able to measure the formation of all four deoxyribonucleotide products simultaneously. Although there is precedent in the literature for HPLC assays that can measure all four products simultaneously, those assays with published total run times and flow rates take 45–180 minutes per run at a flow rate of 0.4–1.5 mL/min, placing buffer and time limitations on the number of samples that can be run as compared to the assay presented here (which takes 10 minutes per run at a flow rate of 0.350 mL/min) [44, 60].

Using the ability to measure all four dNDP products at once, we were able to show how increasing the concentration of one specificity effector at a time while keeping the other specificity effectors concentration constant affected the ratios of the dNDP products under a given set of conditions. When the concentration of any one specificity effector was increased from zero to approximately physiological levels, we saw an increase in enzyme activity on the substrates known to be the cognate pair(s) of that specificity effector; RNR activity on CDP and UDP increased when 200 μM dATP was added and the ratios of dCDP/dUDP to dADP and dGTP increased; RNR activity on ADP increased with addition of 200 μM dGTP and the ratio of dADP to other dNDPs increased considerably; and RNR activity on GDP increased with addition of 200 μM TTP although the combination of 200 μM TTP, 3 mM ATP, 0.2 mM dATP, and 0.10 mM dGTP makes for an RNR that is quite active on ADP substrate as well (Table 2; Fig 8). As previously reported, the presence of specificity regulators increases RNR activity in the 1.5–10 fold range [76, 77]. These data help us appreciate how an increase in the concentration of one effector can impact the ratios of all deoxyribonucleotides in a cell and the importance of cellular processes that keep all nucleotides within the physiological range.

We also see that large increases past the normal physiological range of any effector negatively impact RNR activity. Although dATP is a known allosteric activity inhibitor [78, 79], high concentrations (1 mM) of both dGTP and TTP also dampened overall EcRNR activity on its substrates. The dampening affected the reduction of all four ribonucleotide substrates under variable dATP and TTP conditions, whereas the decrease was not seen for the ADP substrate under variable dGTP conditions but was seen for the other three substrates. The mechanism of activity reduction is unlikely to be due to dGTP and TTP binding to the allosteric activity site, as that site is specific for dATP and ATP [41, 42]. The finding that an imbalance in the deoxyribonucleotide pool can affect overall RNR enzyme activity, which consequently would further impact the overall size and distribution of deoxyribonucleotides in the cell, shows how easily one imbalance can lead to further potentially disastrous imbalances in the cellular environment [29].

We additionally saw other impacts of measuring enzyme activity under pseudo-physiological nucleotide conditions instead of only supplying the enzyme with the necessary components to complete the desired reaction. We found that the concentration of dATP needed to inhibit E. coli class Ia RNR is much higher when ATP is also present at approximately physiological conditions. These results underscore the importance of having the protein in an approximately physiological nucleotide milieu when making conclusions to which one wishes to extend biological relevance.

Many examples of the assay presented here use a standard curve that must be run in triplicate before each set of assays due to day-to-day variability in the mass spectrometer; however, in the case of many assays being done over days or weeks over the course of an experiment, heavy deoxyribonucleotide dNTP standards (0.4 nmoles / injection) can be added to each standard and reaction mixture after the 95°C inactivation step but prior to dephosphorylation via CIP. The internal standards used must match the nucleotide identity of the product being measured in order to closely match the fragmentation and flight path of the desired products. Because the four deoxyribonucleotide assays already use heavy nucleotides as effectors (since dNTPs and dNDPs cannot be distinguished after dephosphorylation), internal standards via heavy nucleotides are not an option for the four deoxyribonucleotide assays, but are options for any single ribonucleotide assay; these assays are still feasible by running same-day standard curves on the mass spectrometer, which can be formulated in advance in volumes that facilitate running many assays and stored stably at room temperature or -20°C prior to use.

The assay presented is a flexible one, allowing for differences in protein concentration, temperature, and reducing agents to be easily accommodated. This flexibility means that a wide variety of RNRs, including the E. coli and S. thermophilus RNRs presented here, can be assayed using this protocol or a modification of this protocol. Proteins such as the S. thermophilus RNR that are thermophilic should be assayed for temperature of unfolding before using heat as a denaturant; however, even enzymes that require very high temperatures for inactivation and may not inactivate immediately upon insertion into the 95°C heat block can still be assayed. The delay on inactivation will be constant across time points, and so the slope of the product generation line that determines enzyme activity will be the same regardless. Alternatively, heating-independent methods for stopping the reaction can be employed such as acid, methanol, or cold [11, 21, 44, 58, 59, 61, 63]. To verify that the method used to stop the reaction is satisfactory and that no refolding of the enzyme has occurred, the enzyme can be assayed following “inactivation” to ensure that there is no measured activity.

Our lab has successfully assayed other RNRs, including the Neisseria gonorrhoeae and human class Ia RNRs, using this assay; these data will be presented in future publications. Additionally, in the absence of physiological reducing agents or during experiments where cloning and purification of one or many organismal Trx and TrxR proteins is not feasible, 10–50 mM dithiothreitol (DTT) can be used as a universal reductant for class Ia RNRs. However, the efficiency of DTT can vary appreciably and optimization of DTT concentration should be performed for each enzyme and enzyme variant [8082]. Finally, the linear range of each of the deoxyribonucleosides is at least in the femtomole or picomole to nanomole range (S5 Fig), meaning that a wide range of activities can be measured.

Future applications of LC-MS/MS for the study of RNRs include determinations of the stoichiometries of nucleotides binding to RNRs and their associated Kds. This assay could be adapted to be less labor intensive through the substitution of manual steps, following generation of the mastermix, with automated liquid handling. We look forward to seeing the ways that this assay is employed to investigate both well-characterized and under-characterized RNRs.

Materials and methods

Reagents were procured from MilliporeSigma unless otherwise noted.

Protein expression and purification

E. coli proteins (NrdA, NrdB, Trx, TrxR)

E. coli NrdA, NrdB, Trx, and TrxR were expressed from codon-optimized pET30(a) vectors as N-terminally His-tagged proteins (EMD; Quintara Biosciences). Expression of all proteins began with a 1:100 inoculation of overnight culture grown from a single colony of T7 Express cells (NEB) into Luria Broth (LB) + 50 ng/μL kanamycin (GoldBio). The cultures were grown at 37°C with shaking at 220 rpm until OD600 reached 0.6–0.8, at which point the cells were moved to 18°C before induction with 1 mM isopropyl ß-D-1-thiogalactopyranoside (IPTG) (Gold Bio). Cells continued shaking overnight (approx. 20–22 hours) before being spun down at 4000 x g for 15 minutes at 4°C and frozen at -20°C until lysis and purification. To begin purification, cells were thawed on ice and resuspended in 30 mL lysis buffer (50 mM sodium phosphate monobasic pH 8.0, 500 mM sodium chloride, 10 mM imidazole, 10% glycerol (VWR), 5 mM beta-mercaptoethanol for NrdA and NrdB; 50 mM tris(hydroxymethyl)aminomethane (Tris) pH 7.6, 300 mM sodium chloride, 30 mM imidazole, 5 mM beta-mercaptoethanol for Trx and TrxR) per 2 L cells. The following was added to the resuspension: 0.1% Triton X-100, one ethylenediaminetetraacetic acid (EDTA)-free protease inhibitor tablet (Roche), 5 μL benzonase, and a small amount (~5 mg) of lysozyme. Once cells were completely resuspended, they were sonicated on ice for 3 minutes and 30 seconds at 70% amplitude with 1 second of sonication on followed by 3 seconds of sonication off. Lysed cells were spun down at 25000 x g for 30 minutes at 4°C before the clarified lysate was loaded onto a 5 mL HisTrap column (GE Life Sciences) equilibrated with lysis buffer. The lysate was batch-bound for one hour using a peristaltic pump running at 1 mL/min before flow-through was collected. The protein was then eluted off of the HisTrap column using a gradient from 4–100% B (B = lysis buffer + 500 mM imidazole) at 2.5 mL/min. Fractions containing the protein of interest were determined using SDS-PAGE (Bio-Rad, 4–20% gel, 200 V) and then were concentrated using a 30 KDa (NrdA and NrdB) or 10 kDa (Trx and TrxR) spin concentrator (Millipore) to a final volume of 1–3 mL. Concentrated protein was injected onto a Superdex S200 16/60 column (GE Life Sciences) equilibrated with 50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) pH 8, 100 mM potassium chloride, 15 mM magnesium chloride, and 10% glycerol for NrdA and NrdB (with the addition of 1 mM DTT [Research Products International] for NrdA) or 20 mM HEPES pH 7.6, 100 mM sodium chloride, 5% glycerol for Trx and TrxR. Purity of the compounds was determined by running an SDS-PAGE gel (4–20%, 200 V; expected molecular weights 85774, 44528, 13612, and 36429 Da for NrdA, NrdB, Trx, and TrxR, respectively). Concentrations of the proteins were determined by A280 (ε = 88590, 62340, 15470, and 20400 M-1cm-1 for NrdA, NrdB, Trx, and TrxR, respectively [per monomer]). Concentration of flavinated TrxR was subsequently determined at 458 nm (ε = 11200 M-1cm-1), which is the molar absorptivity of the flavin cofactor. If necessary, proteins were further concentrated using a 30 kDa (NrdA and NrdB) or 10 kDa (Trx and TrxR) spin concentrator (Millipore) prior to being aliquoted and flash-frozen in liquid nitrogen for storage at -80°C.

Reconstitution of the NrdB di-iron cluster was conducted in an anaerobic (100% nitrogen atmosphere; Airgas or Medtech) MBraun chamber held at 4°C as previously described [51, 78]. Aerobic RNR storage buffer (50 mM HEPES pH 8, 100 mM KCl, 15 mM magnesium chloride, 10% glycerol) was sparged for 30 minutes with argon gas (Airgas or Medtech) and brought into the anaerobic chamber along with approximately 10 mg ferrous ammonium sulfate powder and the protein to be reconstituted (with headspace degassed). Once inside the chamber, the iron ammonium sulfate was dissolved in 1 mL storage buffer and enough iron ammonium sulfate was added dropwise to the protein solution with stirring to reach 5 molar equivalents iron per beta dimer. The reaction was allowed to stir in the chamber for 15 minutes before it was removed from the anaerobic chamber and immediately mixed with oxygen-saturated storage buffer generated by bubbling oxygen (Airgas) through the buffer for 10 minutes prior to use. The volume of oxygen-saturated buffer added equaled 10 molar equivalents of oxygen per beta dimer using the assumption that the concentration of oxygen in saturated buffer is 1.4 mM. Oxygen was then blown over the surface of the protein solution for 2 minutes before protein was spun down at 13,000 x g for 1 minute to remove precipitate. The protein was then applied to a HiPrep 26/10 desalting column (GE Life Sciences) equilibrated with RNR storage buffer in order to remove excess iron from the protein solution before concentration and storage of the protein at -80°C. Radical content was determined to be 1.2 radicals per reconstituted NrdB dimer by electron paramagnetic resonance (EPR; Bruker EMX-Plus) (S6 Fig). EPR parameters were 80K, 10 scans, modulation amplitude 1.5G, center field 3330 G, sweep width 300G, sweep time 20 s, microwave power 38dB.

S. thermophilus proteins (NrdD, NrdG)

S. thermophilus NrdD, originally amplified from a commercial yogurt sample, was cloned into and expressed from a pET15(b) vector as N-terminally His6-tagged protein with a thrombin cleavage sequence in T7Express cells (NEB). Expression began with a 1:200 inoculation of overnight culture grown from a single colony into LB with 50 μM ampicillin (Research Products International) and 50 μM zinc sulfate. The cultures were grown at 37°C with shaking at 220 rpm until OD600 reached 0.6–0.8, at which point the cells were moved to 16°C before induction with 0.5 mM IPTG. Cells continued shaking overnight (approx. 18–20 hours) before being spun down at 4000 x g for 15 minutes at 4°C. The resulting cell pellet was frozen at -80°C until lysis and purification. To begin purification, cells were thawed at room temperature and resuspended in 30 mL buffer A (50 mM HEPES pH 7.6, 300 mM sodium chloride, 1 mM tris(2-carboxyethyl)phosphine [TCEP]) per 2 L cells. The following was added to the resuspension: 0.1% Triton X-100, 0.5 mM phenylmethylsulfonyl fluoride (PMSF), one EDTA-free protease inhibitor tablet (Roche), 5 μL benzonase, and a small amount (~5 mg) of lysozyme. Once cells were completely resuspended, they were nutated at 4°C for 15 min before lysis by sonication on ice for 3 minutes and 30 seconds at 70% amplitude with 1 second of sonication on followed by 3 seconds of sonication off. Lysed cells were spun down at 25000 x g for 40 minutes at 4°C before the clarified lysate was loaded onto a 5 mL HisTrap column equilibrated with buffer A. The lysate was batch-bound for thirty minutes using a peristaltic pump running at 1 mL/min before flow-through was collected. The column was first washed, at a rate of 1.5 mL/min, with 10 column volumes of buffer A, followed by a 5-column volume wash with buffer A supplemented with 10 mM imidazole. The protein was eluted off the HisTrap column using buffer A supplemented 300 mM imidazole. Fractions containing the protein of interest were determined using SDS-PAGE (4–20% gel, 200 V), and were diluted two-fold with buffer A before concentrating using a 50 kDa spin concentrator (Millipore) to a final volume of 3–5 mL. Concentrated protein was injected onto an S200 16/60 column equilibrated with 20 mM HEPES pH 7.6, 100 mM sodium chloride. Purity of the compounds was determined by running an SDS-PAGE gel (4–20%, 200 V; expected molecular weight 85619 Da). Concentrations of the proteins were determined by A280 (ε = 189010 M-1cm-1 [per dimer]). Proteins were further concentrated using a 50 kDa spin concentrator (Millipore) prior to being aliquoted and flash-frozen in liquid nitrogen for storage at -80°C.

S. thermophilus NrdG was expressed from a pET28(a) vector as a codon optimized His6-tagged protein with a thrombin cleavage site (codon optimized sequence WP_011681737.1 synthesized by Genscript) in BL21 (DE3) cells (Novagen). Cultures, supplemented with kanamycin at 50 ng/μL (GoldBio), were grown to an OD600 of 0.6 before induction with 1 mM IPTG. Cells continued shaking overnight at 16°C. Cells were pelleted by centrifugation and resuspended in 10 mL/1L of culture in 50 mM HEPES pH 7.6, 300 mM sodium chloride, 5% glycerol, 1 mM TCEP, and 0.5 mM PMSF. Cells were lysed by sonication on ice for 4 minutes at 70% amplitude with 1 second of sonication on followed by 3 seconds of sonication off. The lysate was clarified by centrifugation at 25,000 x g for 40 minutes in the presence of 1 μL benzonase per 1 L of culture. Lysate was filtered and applied to 10 mL of TALON resin (GE Life Sciences), then washed with 20 mM HEPES pH 7.6, 100 mM potassium chloride, 1% (v/v) glycerol supplemented with 15 mM imidazole. Protein was eluted with the 20 mM HEPES pH 7.6, 100 mM potassium chloride, 1% (v/v) glycerol supplemented with 150 mM imidazole. Protein was buffer exchanged to remove imidazole and glycerol, then concentrated. His6-tag cleavage was completed next by incubation at 4°C overnight with 1 U of thrombin (GE Life Sciences) per mg of protein. Thrombin was quenched by addition of 0.5 mM PMSF and tag-free protein was isolated by subtractive TALON. Tag-free protein was concentrated to ~10 mg/mL (using Bradford correction value of 0.69), sealed in a bottle, and the headspace degassed by sparging with argon gas. Protein was brought into an anaerobic chamber with a 100% Nitrogen atmosphere (MBraun) maintained at 4°C, opened, and DTT added to 5 mM. Protein sat vented for 5 days in the MBraun at 4°C before the entire stock was reconstituted.

StNrdG reconstitution

Before reconstitution in the MBraun chamber, DTT was added to a final concentration of 10 mM and protein was diluted with 20 mM HEPES pH 7.6, 100 mM KCl, 10 mM DTT (Buffer A1) to a concentration of 100 uM monomer (~2 mg/mL). Reconstitution was initiated by adding 5 equivalents of iron (III) chloride (FeCl3), then sodium sulfide (Na2S), swirling after each addition and incubating for 4 hours. Reconstituted protein was spun quickly, concentrated, then desalted by anaerobic size exclusion on an 16/60 Superdex 200 (GE Lifesciences) using buffer A1. This procedure yielded ~60% recovery of protein at ~4.5 Fe/monomer as measured by a ferene assay as previously described [83], with protein quantified by Bradford protein assay with a correction of 0.69. Reconstituted protein was stored in a 4°C refrigerator inside an anaerobic MBraun chamber.

Determination of glycyl radical content of StNrdD

Glycyl radical was installed on StNrdD via the activation reaction with StNrdG described below, then glycyl radical content was determined through EPR. Inside an anaerobic MBraun chamber, in a clear Eppendorf tube, 4 μM StNrdG monomer, 0.2 mM S-adenosylmethionine (AdoMet), 50 μM 5-deazariboflavin, 1% glycerol, and 10 μM StNrdD dimer were diluted and mixed in 30 mM potassium chloride, 30 mM bicine, pH 7.6. The StNrdD dimer was added last and, upon addition, the mixture was illuminated for 1 hr using a 2500 lumen LED bulb and the MBraun chamber light. After, the entire reaction mixture was transferred into an EPR tube, frozen in liquid nitrogen, and removed from the anaerobic chamber. Potassium nitrosodisulfonate (Fremy’s salt) dissolved in anaerobic 30 mM potassium chloride, 30 mM bicine, pH 7.6 buffer were used as radical standards for EPR quantification of glycyl radical (S7 Fig). EPR (Bruker EMX-Plus) parameters were 80 K, 10 scans, modulation amplitude 3 G, center field 3350 G, sweep width 200 G, sweep time 21 s, microwave power 52 dB.

Determination of protein melting temperature of StNrdD

All data were collected on a LightCycler 480 (Roche) and analysis was done with LightCycler 480 Software release 1.5.0 SP3 (version 1.5.0.39). First, optimal ratios of StNrdD to SYPRO Orange (Sigma) dye were determined through performing the melting protocol while screening across 5X-20X SYPRO Orange and 0.5–10 μM StNrdD. SYPRO Orange and StNrdD stock solutions were diluted in 1X assay buffer (30 mM Tris pH 7.5, 30 mM potassium chloride, 10 mM magnesium sulfate), mixed in a white LightCycler 480 MultiWell Plate 96 plate (Roche), and sealed with a clear sealing film (Axygen). The melting protocol was as follows: the first target temperature was 20°C, with a hold of 15 seconds and a ramp rate of 4.4°C/s. The second target temperature was 99°C, with a continuous acquisition mode of 10 acquisitions per °C and a ramp rate of 0.06°C/s. The third target temperature was 20°C, with a hold of 15 seconds and a ramp rate of 2.2°C/s. Protein melting curves were analyzed within the LightCycler 480 software, using the Tm Calling analysis to plot melting peaks (the negative first derivative of the melting curves). Melting temperatures were calculated through manual picking of the negative peaks of each run, within the LightCycler 480 software. The ratio of 4 μM StNrdD and 15X SYPRO Orange produced optimal curves. The melting temperature of StNrdD in the presence of nucleotides at assay concentrations was then determined. StNrdD, diluted in 1X assay buffer, was mixed with 1 mM GTP, 1 mM TTP and 3 mM ATP or 3 mM dATP and incubated at 37°C for 2 min before addition of SYPRO Orange and further dilution with 1X assay buffer, supplemented with nucleotides to a ratio of 4 μM StNrdD and 15X SYPRO Orange. The same melting protocol and analysis was then performed as previously described.

Activity assays

Nucleotide preparation

Nucleotides and deoxyribonucleotides (including heavy deoxyribonucleotides) were purchased from Santa Cruz Biotechnology or Sigma Aldrich. Nucleotides were dissolved to approximately 100 mM stock concentration in 50 mM HEPES and the pH was adjusted to approximately 8 before freezing in small aliquots for use in assays. Exact concentration was determined using UV/Vis spectroscopy and molar absorptivity values [84]. Heavy (13C/15N) nucleotides were shipped at 100 mM in 5 mM Tris buffer and were not diluted or buffer exchanged prior to use. All nucleotides were stored at -70°C.

Optimization of assay conditions

To assay how quickly inactivation occurred (S1 Table), 40 μL of water was placed into a thin-walled PCR tube (USA Scientific) and was incubated for 5 minutes at 37°C in a dry bath. The probe end of a multimeter set to the temperature setting was placed into the water and the tube was subsequently placed into a thermocycler set to 95°C. Time to reach 45°C, 60°C, and 85°C was measured for five aliquots and averaged. A control was also completed where the probe was directly put into a 95°C solution of water and the time it took to reach 37°C, 85°C, and 95°C was recorded. Note that because of the method of assaying temperature of the solution, the top of the thermocycler could not be closed during the temperature assay, and so heating may occur slightly more quickly during the assay.

Optimization of the dephosphorylation step (S2 Fig) was completed on solutions of 3 mM ATP and 1 mM CTP in class Ia assay buffer (50 mM HEPES pH 7.6, 15 mM magnesium chloride, 10 mM ethylenediaminetetraacetic acid). Standards were composed of 3 mM adenosine and 1 mM cytidine in class Ia assay buffer and were not treated with calf intestinal phosphatase. Varying volumes of calf intestinal phosphatase (Quick CIP; New England Biolabs) (0.5, 1, 3, or 5 μL) were added to 40 μL of solution and then were incubated in a thermocycler for 10 minutes, 30 minutes, 2 hours, or overnight (16 hours) prior to inactivation for 10 minutes at 85°C. Samples were then filtered through a 0.2 μm filter (Costar) prior to analysis of A (m/z 268.2 -> 135.9) and C (m/z 243.2 -> 112.1) nucleosides via LC-MS/MS as described below. Optimization of the use of CutSmart buffer (New England Biolabs) was similarly performed on a solution of 40 μL of 3 mM ATP and 1 mM CTP in class Ia assay buffer. To this solution, 1 μL of CIP was added and either 4 μL of CutSmart buffer or 4 μL of assay buffer was added prior to dephosphorylation for 2 hours at 37°C. The CIP was inactivated at 85°C for 10 minutes prior to filtering in a 0.2 μm filter (Costar) and analysis of A and C nucleosides via LC-MS/MS as described below.

Optimization of standard curve conditions (S3 Fig) was completed using solutions containing 0–100 μM of either: (1) each of the four deoxyribonucleosides (dA, dC, dG, and dU), (2) each of the four deoxyribonucleotide products (dADP, dCDP, dGDP, and dUTP [used due to an unavailability of dUDP]), or (3) each of the four deoxyribonucleotide products in the presence of 3 mM ATP as an activity effector as well as the four substrates (100 μM ADP, 200 μM GDP, 50 μM UDP, 70 μM CDP). The three conditions were each completed in triplicate. The two conditions containing (deoxy)ribonucleotides were treated with 1 μL Quick CIP (New England Biolabs) for 2 hours at 37°C prior to inactivation for 10 minutes at 85°C and filtering through a 0.2 μm filter (Costar). The condition containing only deoxyribonucleosides was also filtered through a 0.2 μm filter, and then all three conditions were injected onto the LC-MS/MS for analysis of dA, dC, dG, and dU as described below.

Aerobic assay

This assay was used to generate Figs 3, 4, 68. All components of the assay (class Ia assay buffer, nucleotides, NrdA, Trx, TrxR, NADPH) minus NrdB were mixed in a reaction to generate 240 μL mastermix (final volume after NrdB addition) and incubated at 37°C for two minutes. All proteins used in these assays have intact His tags, but it has been shown that His tags do not substantially interfere with NrdA and NrdB activity [74]. To ensure that re-reduction was not the rate-limiting step, we used a large excess (60x) of Trx to ensure full and rapid reduction of NrdA. Nucleotide concentrations were generally modeled after physiological concentrations and are indicated below each Fig [71, 72]. After two minutes, a zero time point was generated by removing a volume of mastermix to a thin-wall PCR tube that would equal 40 μL after the addition of NrdB and was transferred to a thermocycler or heat block set at 95°C. After incubation for 2 minutes at 95°C to inactivate all proteins present, a volume of NrdB was added to the zero point to raise the volume to 40 μL and equal the final concentration of NrdB in the rest of the assay. The assay was then initiated by the addition of NrdB to the 37°C mastermix and 40 μL aliquots were taken into a thin-wall PCR tube at 30, 60, 90, and 120 s after initiation and immediately transferred to a 95°C thermocycler to stop the reaction. After all time points were taken, the time points were kept at 95°C for 2 more minutes and then cooled to 37°C for 10 minutes, at which point 1 μL calf alkaline intestinal phosphatase (Quick CIP; New England Biolabs) was added to each tube. The dephosphorylation reaction was allowed to proceed for 2 hours at 37°C prior to inactivation of the CIP at 85°C for 2 minutes. For CDP reduction assays, samples containing internal standards (Fig 6), 1 μL of 1.6 mM heavy dCTP (13C/15N, Santa Cruz Biotechnology) was added to each 40 μL standard prior to treatment with CIP. The samples were then filtered through a 0.2 μm spin filter plate (Pall) for 10 minutes at 1100 x g. Flow through was transferred to an LC-MS vial (Agilent Technologies) with a 150 μL insert prior to loading and running on the LC-MS/MS.

Standards consisted of 40 μL either dCDP (E. coli original assays; Figs 3, 4 and 6) or a mixture of dADP, dCDP, dGDP, and dUTP (E. coli 4 dN assays; Figs 7 and 8) in a 40 μL volume at concentrations of 0, 20, 40, 60, 80, and 100 μM of each nucleotide. All standards also contained 3 mM ATP. For each standard curve, standards were generated in triplicate, allowed to sit for 2 minutes at 37°C, and then transferred to 95°C for 2 minutes before being treated identically to inactivated samples from that point onwards (treatment with CIP, filtration, and transfer to vials). For standard curves containing internal standards (Fig 6), 1 μL of 1.6 mM heavy dCTP (13C/15N, Santa Cruz Biotechnology) was added to each 40 μL standard prior to treatment with CIP.

Anaerobic assay

This assay was used to generate Fig 5. In an anaerobic chamber (Mbraun) protein mastermix containing buffer (30 mM Tris pH 7.5, 30 mM potassium chloride, 10 mM magnesium sulfate), DTT (5 mM), sodium formate (12.5 mM), and activated StNrdD (0.10 μM; still in mixture with StNrdG from the activation reaction) and a nucleotide mastermix containing all nucleotides needed (1 mM substrate GDP, 1 mM specificity effector TTP, 3 mM allosteric activator ATP [ATP condition] or 3 mM allosteric inhibitor dATP [dATP condition]) were prepared and mixed separately. All components were mixed to jointly generate a 250 μL combined mastermix. All components were gas exchanged to remove oxygen either by sparging with argon gas before bringing into the anaerobic chamber, or through passive gas exchange through venting in the anaerobic chamber for one hour up to overnight. The protein mastermix was incubated at 37°C for ten minutes and the nucleotide mastermix was incubated at 37°C for one minute. After incubation, a zero time point was generated by adding protein mastermix (40 μL minus the amount of nucleotide mastermix needed to add to equal the concentrations used in the rest of the assay) to a thin-walled PCR tube in a heat block at 95°C. After a two-minute incubation at 95°C to deactivate all proteins, a volume of nucleotide mastermix was added to the vial to raise the volume to 40 μL and equal the final concentration of nucleotides in the rest of the assay. The zero point was mixed and incubated for at least an additional two minutes. The assay was initiated by the addition of the nucleotide mastermix to the protein mastermix. At 30, 60, 90, and 120 seconds after initiation, 40 μL aliquots were taken and immediately transferred to a thin-walled PCR tube in 95°C heat block to stop the reaction. The assay mixture was mixed before each aliquot was taken, and time points were timed so that the addition of assay mixture to the thin-wall PCR tube at 95°C signified the end of a time point. After all time points were taken, the aliquots were kept at 95°C for two more minutes to fully inactivate protein, at which point samples were removed from the anaerobic chamber. The samples were then treated with CIP, filtered, and transferred to LC-MS vials in an identical manner to the aerobic assay samples.

Standards consisted of 40 μL dGTP at concentrations of 0, 5, 10, 20, 30, 40, 60, 80, and 100 μM. All standards also contained 3 mM ATP, 1 mM GTP, 1 mM TTP, 5 mM DTT, 12.5 mM sodium formate in 30 mM Tris pH 7.5, 20 mM KCl, 10 mM MgSO4. For each standard curve, standards were generated in triplicate, allowed to sit for 2 minutes at 37°C, and then transferred to 95°C for 2 minutes before being treated identically to inactivated samples from that point onwards (treatment with CIP, filtration, and transfer to vials).

LC-MS/MS analysis

A Synergi 2.5 μm Fusion-RP 100 Å LC column 100x2mm, particle size 2.5 (Phenomenex) with corresponding guard column was used for all experiments. LC-MS/MS was completed using an Agilent 6410 tandem triple quadrupole mass spectrometer connected to an Agilent 1100 HPLC system with 5 mM ammonium acetate pH 5.3 in water (buffer A) and acetonitrile (buffer B). LC-MS-grade ammonium acetate and acetic acid (Fisher Scientific) were used to generate buffer A, and buffer A was stored as a 1000x stock solution at -20°C and diluted within one week of use. The flow rate was 0.350 mL/min throughout and separation was achieved over a 5 minute gradient from 3 to 5 percent B (S3 Table).

Column oven temperature was held at 35°C throughout the runs. UV traces were monitored at 270 nm and desired analytes were monitored using MRM mode (fragmentor 165 V, dwell time 200 ms, collision energy 20 V). Analytes measured and their MRM parameters are indicated in S2 Table. Note that in cases where only one analyte was being measured, the program did not include the other analytes. Source parameters were gas temp 350°C, gas flow 9 L/min, nebulizer 40 psi, capillary 4000 V (positive ion mode), and the electron multiplier voltage was set to 550 V. Injection volume was 10 μL per injection. All data processing and integration was completed using the Agilent MassHunter Qualitative Analysis program.

Determination of protein activity from LC-MS/MS data

The MRM peak for each analyte was integrated and the average +/- standard deviation integration of each standard was plotted against nmoles standard injected. A line of best fit was drawn through the standards and used to calculate the nmoles analyte(s) injected for each time point in the assay from the peak integrations. The nmoles analyte were graphed versus time in minutes and the slope of the line of best fit (in nmoles / minute) was calculated. The slope was divided by the total mg of the limiting protein present in each 10 μL injection to yield nmoles/mg-min for each time course. For aerobic assays, limiting protein was total mg of either NrdA or NrdB (not adjusted for radical content); for anaerobic assays, limiting protein was total mg activated NrdD present, with total mg NrdD adjusted based on concentration of glycyl radical identified in EPR analysis assuming maximal radical concentration of 2 radicals per dimer. The average activity and standard error of the mean of three time courses was taken for each condition. All graphical analysis was completed using Igor Pro v6.37.

Supporting information

S1 Table. Time taken for water to reach various temperatures upon insertion into a 95°C thermocycler.

Each temperature was assayed five times using 40 μL of water in a thin-walled PCR tube that had an initial temperature of 37°C.

(DOCX)

S2 Table. MRM parameters for each of the four deoxyribonucleoside products and their corresponding internal standards quantified in the RNR reaction.

(DOCX)

S3 Table. LC-MS program used for the LC-MS/MS experiments.

(DOCX)

S1 Fig. Protein melting peaks of StNrdD in different nucleotide conditions.

Protein melting peaks of StNrdD with no nucleotides (StNrdD alone) or 1 mM TTP and GTP and either 3 mM ATP or 3 mM dATP. Table insert summarizes the melting temperature of StNrdD under the three conditions, which equates to the temperature at the negative peak of each curve.

(TIF)

S2 Fig. Optimization of dephosphorylation step using calf intestinal phosphatase (CIP).

(A) Variation in dephosphorylation based on volume CIP added and incubation time (at 37°C) on a solution of 3 mM ATP and 1 mM CTP. Dephosphorylation was determined by adenosine MRM signal and was compared to a standard of 3 mM adenosine nucleoside. 1 μL CIP addition and incubation for 2 hours was used for all further studies. (B) Impact of the addition of CutSmart buffer to the CIP incubation mixture on a solution of 3 mM ATP and 1 mM CTP. Dephosphorylation was determined by cytidine MRM signal and was compared to a standard of 1 mM cytidine nucleoside. No CutSmart buffer was added in any further studies.

(TIF)

S3 Fig. Standard curve optimization.

The presence of substrate and effector nucleosides and/or phosphates in addition to the measured deoxyribonucleoside standard is essential in generation of accurate standard curves. A comparison of dA, dC, dG, and dU standard curves generated either from deoxyribonucleotide triphosphates in the presence of substrates and effectors (navy), deoxyribonucleotide triphosphates but no substrates or effectors (purple), or only deoxyribonucleosides (no phosphates; light blue). For conditions where nucleotides were present, nucleotides were treated with CIP prior to analysis by mass spectrometry. Concentrations of substrate and effector nucleotides were as follows: ADP (110 μM), GDP (200 μM), UDP (50 μM), CDP (70 μM), ATP (3 mM). All products measured by LC-MS/MS ranged from 0–100 μM.

(TIF)

S4 Fig. TIC and MRM curves for the four ribonucleotide substrate experiment depicted in Fig 7.

(A) TIC and MRM curves for each of the four standard curves. (B) TIC and MRM curves for the activity assay. The above condition contained Trx (30 μM), TrxR (0.5 μM), NADPH (200 μM), ATP (3000 μM), dATP (500 μM), TTP (250 μM), dGTP (100 μM), CDP (70 μM), UDP (50 μM), GDP (200 μM), ADP (110 μM), NrdA (0.1 μM dimer), and NrdB (0.5 μM dimer).

(TIF)

S5 Fig. Limits of detection of the four deoxynucleosides on the Agilent 6410 system.

(A) Lower limit of detection for each of the four deoxynucleosides. (B) Standard curves are linear at up to 10 nmoles injected deoxyribonucleoside for each product. Note that the upper limit of detection and the upper linear range are both likely higher but are not anticipated to be relevant to RNR assays. Each data point is the mean ± standard error of the mean of three replicates.

(TIF)

S6 Fig

EPR spectra of native (green) and reconstituted (blue) NrdB. EPR parameters were 80K, 10 scans, center field 3330 G, sweep width 300 G, sweep time 20 s, microwave power 38dB, modulation amplitude 1.5G. Double integrals were 134.5 and 580.6 for 100 μM native and reconstituted protein, respectively, leading to radical content of 0.3 and 1.2 radicals per dimer, respectively.

(TIF)

S7 Fig. EPR spectra of the glycyl radical in wild-type StNrdD.

EPR parameters were 80K, 10 scans, modulation amplitude 3G, center field 3350 G, sweep width 200G, sweep time 21 s, microwave power 52dB.

(TIF)

Acknowledgments

The authors gratefully acknowledge the support of Dr. Michael DeMott at the Center for Environmental Health Sciences for valuable discussions and troubleshooting of the LC-MS/MS assay and instrumentation, and Michael A. Funk for cloning S. thermophilus NrdD. The authors additionally thank Dr. Mary Andorfer, Dr. Kelsey Miller, and Alison Biester for their assistance with collection of EPR spectra.

Data Availability

All relevant data are within the manuscript and its Supporting Information files.

Funding Statement

This work was supported by NIH grant GM126982 to C.L.D and NSF GRFP 2017246757 to T.S.L. as well as NIH T32 Training Grant 5T32GM007287 awarded to the MIT Biology Department. C.L.D is a Howard Hughes Medical Institute Investigator and Senior Fellow for the Canadian Institute for Advanced Research Bio-Inspired Solar Energy program. Support for all LC-MS/MS data collection and analysis was provided to the MIT Center for Environmental Health Sciences (CEHS) by a core center grant P30-ES002109 from the National Institute of Environmental Health Sciences, National Institutes of Health. Support for the thermal denaturation assay was provided to the MIT BioMicro Center by the Koch Institute Support (core) Grant P30-CA14051 from the National Cancer Institute. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Aye Y, Brignole EJ, Long MJC, Chittuluru J, Drennan CL, Asturias FJ, et al. Clofarabine Targets the Large Subunit (α) of Human Ribonucleotide Reductase in Live Cells by Assembly into Persistent Hexamers. Chemistry & Biology. 2012;19: 799–805. doi: 10.1016/j.chembiol.2012.05.015 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Greene BL, Kang G, Cui C, Bennati M, Nocera DG, Drennan CL, et al. Ribonucleotide Reductases: Structure, Chemistry, and Metabolism Suggest New Therapeutic Targets. Annual Review of Biochemistry. 2020;89: 45–75. doi: 10.1146/annurev-biochem-013118-111843 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Moorthy NSHN, Cerqueira NMFSA, Ramos MJ, Fernandes PA. Development of ribonucleotide reductase inhibitors: a review on structure activity relationships. Mini Rev Med Chem. 2013;13: 1862–1872. doi: 10.2174/13895575113136660090 [DOI] [PubMed] [Google Scholar]
  • 4.Narasimhan J, Letinski S, Jung S, Gerasyuto A, Wang J, Arnold M, et al. Ribonucleotide reductase, a novel target for gonorrhea. bioRxiv. 2020; 2020.11.19.389957. doi: 10.1101/2020.11.19.389957 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Shao J, Liu X, Zhu L, Yen Y. Targeting ribonucleotide reductase for cancer therapy. Expert Opinion on Therapeutic Targets. 2013;17: 1423–1437. doi: 10.1517/14728222.2013.840293 [DOI] [PubMed] [Google Scholar]
  • 6.Wisitpitthaya S, Zhao Y, Long MJC, Li M, Fletcher EA, Blessing WA, et al. Cladribine and Fludarabine Nucleotides Induce Distinct Hexamers Defining a Common Mode of Reversible RNR Inhibition. ACS Chem Biol. 2016;11: 2021–2032. doi: 10.1021/acschembio.6b00303 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Nordlund P, Reichard P. Ribonucleotide Reductases. Annual Review of Biochemistry. 2006;75: 681–706. doi: 10.1146/annurev.biochem.75.103004.142443 [DOI] [PubMed] [Google Scholar]
  • 8.Torrents E. Ribonucleotide reductases: essential enzymes for bacterial life. Front Cell Infect Microbiol. 2014;4. doi: 10.3389/fcimb.2014.00004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Brown NC, Canellakis ZN, Lundin B, Reichard P, Thelander L. Ribonucleoside Diphosphate Reductase. Purification of the two Subunits, Proteins B1 and B2. European Journal of Biochemistry. 1969;9: 561–573. doi: 10.1111/j.1432-1033.1969.tb00646.x [DOI] [PubMed] [Google Scholar]
  • 10.Reichard P, Baldesten A, Rutberg L. Formation of Deoxycytidine Phosphates from Cytidine Phosphates in Extracts from Escherichia coli. J Biol Chem. 1961;236: 1150–1157. [PubMed] [Google Scholar]
  • 11.Blaesi EJ, Palowitch GM, Hu K, Kim AJ, Rose HR, Alapati R, et al. Metal-free class Ie ribonucleotide reductase from pathogens initiates catalysis with a tyrosine-derived dihydroxyphenylalanine radical. PNAS. 2018; 201811993. doi: 10.1073/pnas.1811993115 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Rose HR, Ghosh MK, Maggiolo AO, Pollock CJ, Blaesi EJ, Hajj V, et al. Structural Basis for Superoxide Activation of Flavobacterium johnsoniae Class I Ribonucleotide Reductase and for Radical Initiation by Its Dimanganese Cofactor. Biochemistry. 2018;57: 2679–2693. doi: 10.1021/acs.biochem.8b00247 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Rose HR, Maggiolo AO, McBride MJ, Palowitch GM, Pandelia M-E, Davis KM, et al. Structures of class Id ribonucleotide reductase catalytic subunits reveal a minimal architecture for deoxynucleotide biosynthesis. Biochemistry. 2019. [cited 18 Mar 2019]. doi: 10.1021/acs.biochem.8b01252 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Ruskoski TB, Boal AK. The periodic table of ribonucleotide reductases. J Biol Chem. 2021; 101137. doi: 10.1016/j.jbc.2021.101137 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Licht S, Gerfen GJ, Stubbe J. Thiyl Radicals in Ribonucleotide Reductases. Science. 1996. [cited 8 Sep 2021]. Available: https://www.science.org/doi/abs/10.1126/science.271.5248.477 [DOI] [PubMed] [Google Scholar]
  • 16.Tamao Y, Blakley RL. Cobamides and ribonucleotide reduction. XI. Direct spectrophotometric observation of an intermediate formed from deoxyadenosylcobalamin in ribonucleotide reduction. Biochemistry. 1973;12: 24–34. doi: 10.1021/bi00725a005 [DOI] [PubMed] [Google Scholar]
  • 17.Schell E, Nouairia G, Steiner E, Weber N, Lundin D, Loderer C. Structural determinants and distribution of phosphate specificity in ribonucleotide reductases. Journal of Biological Chemistry. 2021;297. doi: 10.1016/j.jbc.2021.101008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Inukai S, Sato K, Shimizu S. Purification and Properties of Vitamin B12-dependent Ribonucleotide Reductase from Rhizobium meliloti. Agricultural and Biological Chemistry. 1979;43: 637–646. doi: 10.1080/00021369.1979.10863489 [DOI] [Google Scholar]
  • 19.Eliasson R, Pontis E, Jordan A, Reichard P. Allosteric Control of Three B12-dependent (Class II) Ribonucleotide Reductases IMPLICATIONS FOR THE EVOLUTION OF RIBONUCLEOTIDE REDUCTION. J Biol Chem. 1999;274: 7182–7189. doi: 10.1074/jbc.274.11.7182 [DOI] [PubMed] [Google Scholar]
  • 20.Fontecave M. [18] Ribonucleotide reductase from Pyrococcus furiosus. Methods in Enzymology. Academic Press; 2001. pp. 215–227. doi: 10.1016/S0076-6879(01)34470-1 [DOI] [PubMed] [Google Scholar]
  • 21.Loderer C, Jonna VR, Crona M, Rozman Grinberg I, Sahlin M, Hofer A, et al. A unique cysteine-rich zinc finger domain present in a majority of class II ribonucleotide reductases mediates catalytic turnover. Journal of Biological Chemistry. 2017;292: 19044–19054. doi: 10.1074/jbc.M117.806331 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Loderer C, Holmfeldt K, Lundin D. Non-host class II ribonucleotide reductase in Thermus viruses: sequence adaptation and host interaction. PeerJ. 2019;7: e6700. doi: 10.7717/peerj.6700 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Booker S, Stubbe J. Cloning, sequencing, and expression of the adenosylcobalamin-dependent ribonucleotide reductase from Lactobacillus leichmannii. Proceedings of the National Academy of Sciences. 1993;90: 8352–8356. doi: 10.1073/pnas.90.18.8352 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Gleason FK, Olszewski NE. Isolation of the gene for the B12-dependent ribonucleotide reductase from Anabaena sp. strain PCC 7120 and expression in Escherichia coli. J Bacteriol. 2002;184: 6544–6550. doi: 10.1128/JB.184.23.6544-6550.2002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Eliasson R, Fontecave M, Jörnvall H, Krook M, Pontis E, Reichard P. The anaerobic ribonucleoside triphosphate reductase from Escherichia coli requires S-adenosylmethionine as a cofactor. Proc Natl Acad Sci U S A. 1990;87: 3314–3318. doi: 10.1073/pnas.87.9.3314 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.King DS, Reichard P. Mass Spectrometric Determination of the Radical Scission Site in the Anaerobic Ribonucleotide Reductase of Escherichia coli. Biochemical and Biophysical Research Communications. 1995;206: 731–735. doi: 10.1006/bbrc.1995.1103 [DOI] [PubMed] [Google Scholar]
  • 27.Torrents E, Eliasson R, Wolpher H, Gräslund A, Reichard P. The anaerobic ribonucleotide reductase from Lactococcus lactis. Interactions between the two proteins NrdD and NrdG. J Biol Chem. 2001;276: 33488–33494. doi: 10.1074/jbc.M103743200 [DOI] [PubMed] [Google Scholar]
  • 28.Wei Y, Funk MA, Rosado LA, Baek J, Drennan CL, Stubbe J. The class III ribonucleotide reductase from Neisseria bacilliformis can utilize thioredoxin as a reductant. PNAS. 2014;111: E3756–E3765. doi: 10.1073/pnas.1414396111 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Ahluwalia D, Schaaper RM. Hypermutability and error catastrophe due to defects in ribonucleotide reductase. PNAS. 2013;110: 18596–18601. doi: 10.1073/pnas.1310849110 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Ahluwalia D, Bienstock RJ, Schaaper RM. Novel mutator mutants of E. coli nrdAB ribonucleotide reductase: insight into allosteric regulation and control of mutation rates. DNA Repair (Amst). 2012;11: 480–487. doi: 10.1016/j.dnarep.2012.02.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Kumar D, Abdulovic AL, Viberg J, Nilsson AK, Kunkel TA, Chabes A. Mechanisms of mutagenesis in vivo due to imbalanced dNTP pools. Nucleic Acids Res. 2011;39: 1360–1371. doi: 10.1093/nar/gkq829 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Mathews CK. DNA precursor metabolism and genomic stability. FASEB J. 2006;20: 1300–1314. doi: 10.1096/fj.06-5730rev [DOI] [PubMed] [Google Scholar]
  • 33.Watt DL, Buckland RJ, Lujan SA, Kunkel TA, Chabes A. Genome-wide analysis of the specificity and mechanisms of replication infidelity driven by imbalanced dNTP pools. Nucleic Acids Res. 2016;44: 1669–1680. doi: 10.1093/nar/gkv1298 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Larsson KM, Andersson J, Sjöberg BM, Nordlund P, Logan DT. Structural basis for allosteric substrate specificity regulation in anaerobic ribonucleotide reductases. Structure. 2001;9: 739–750. doi: 10.1016/s0969-2126(01)00627-x [DOI] [PubMed] [Google Scholar]
  • 35.Zimanyi CM, Chen PY-T, Kang G, Funk MA, Drennan CL. Molecular basis for allosteric specificity regulation in class Ia ribonucleotide reductase from Escherichia coli. Joshua-Tor L, editor. eLife. 2016;5: e07141. doi: 10.7554/eLife.07141 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Andersson J, Westman M, Hofer A, Sjoberg BM. Allosteric regulation of the class III anaerobic ribonucleotide reductase from bacteriophage T4. J Biol Chem. 2000;275: 19443–19448. doi: 10.1074/jbc.M001490200 [DOI] [PubMed] [Google Scholar]
  • 37.Larsson K-M, Jordan A, Eliasson R, Reichard P, Logan DT, Nordlund P. Structural mechanism of allosteric substrate specificity regulation in a ribonucleotide reductase. Nat Struct Mol Biol. 2004;11: 1142–1149. doi: 10.1038/nsmb838 [DOI] [PubMed] [Google Scholar]
  • 38.Reichard P. Ribonucleotide reductases: substrate specificity by allostery. Biochem Biophys Res Commun. 2010;396: 19–23. doi: 10.1016/j.bbrc.2010.02.108 [DOI] [PubMed] [Google Scholar]
  • 39.Torrents E, Buist G, Liu A, Eliasson R, Kok J, Gibert I, et al. The anaerobic (class III) ribonucleotide reductase from Lactococcus lactis. Catalytic properties and allosteric regulation of the pure enzyme system. J Biol Chem. 2000;275: 2463–2471. doi: 10.1074/jbc.275.4.2463 [DOI] [PubMed] [Google Scholar]
  • 40.Aravind L, Wolf YI, Koonin EV. The ATP-cone: an evolutionarily mobile, ATP-binding regulatory domain. J Mol Microbiol Biotechnol. 2000;2: 191–194. [PubMed] [Google Scholar]
  • 41.Eriksson M, Uhlin U, Ramaswamy S, Ekberg M, Regnström K, Sjöberg B-M, et al. Binding of allosteric effectors to ribonucleotide reductase protein R1: reduction of active-site cysteines promotes substrate binding. Structure. 1997;5: 1077–1092. doi: 10.1016/s0969-2126(97)00259-1 [DOI] [PubMed] [Google Scholar]
  • 42.Brown NC, Reichard P. Role of effector binding in allosteric control of ribonucleoside diphosphate reductase. Journal of Molecular Biology. 1969;46: 39–55. doi: 10.1016/0022-2836(69)90056-4 [DOI] [PubMed] [Google Scholar]
  • 43.Jonna VR, Crona M, Rofougaran R, Lundin D, Johansson S, Brännström K, et al. Diversity in Overall Activity Regulation of Ribonucleotide Reductase. Journal of Biological Chemistry. 2015;290: 17339–17348. doi: 10.1074/jbc.M115.649624 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Hendricks SP, Mathews CK. Regulation of T4 phage aerobic ribonucleotide reductase. Simultaneous assay of the four activities. J Biol Chem. 1997;272: 2861–2865. doi: 10.1074/jbc.272.5.2861 [DOI] [PubMed] [Google Scholar]
  • 45.Hofer A, Ekanem JT, Thelander L. Allosteric regulation of Trypanosoma brucei ribonucleotide reductase studied in vitro and in vivo. J Biol Chem. 1998;273: 34098–34104. doi: 10.1074/jbc.273.51.34098 [DOI] [PubMed] [Google Scholar]
  • 46.Lundin D, Berggren G, Logan DT, Sjöberg B-M. The Origin and Evolution of Ribonucleotide Reduction. Life (Basel). 2015;5: 604–636. doi: 10.3390/life5010604 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Parker MJ, Maggiolo AO, Thomas WC, Kim A, Meisburger SP, Ando N, et al. An endogenous dAMP ligand in Bacillus subtilis class Ib RNR promotes assembly of a noncanonical dimer for regulation by dATP. Proc Natl Acad Sci U S A. 2018;115: E4594–E4603. doi: 10.1073/pnas.1800356115 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Aurelius O, Johansson R, Bågenholm V, Lundin D, Tholander F, Balhuizen A, et al. The Crystal Structure of Thermotoga maritima Class III Ribonucleotide Reductase Lacks a Radical Cysteine Pre-Positioned in the Active Site. PLOS ONE. 2015;10: e0128199. doi: 10.1371/journal.pone.0128199 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Moore EC, Peterson D, Yang LY, Yeung CY, Neff NF. Separation of ribonucleotides and deoxyribonucleotides on columns of borate covalently linked to cellulose. Application to the assay of ribonucleoside diphosphate reductase. Biochemistry. 1974;13: 2904–2907. doi: 10.1021/bi00711a020 [DOI] [PubMed] [Google Scholar]
  • 50.Steeper JR, Steuart CD. A rapid assay for CDP reductase activity in mammalian cell extracts. Analytical Biochemistry. 1970;34: 123–130. doi: 10.1016/0003-2697(70)90092-8 [DOI] [PubMed] [Google Scholar]
  • 51.Yee CS, Seyedsayamdost MR, Chang MCY, Nocera DG, Stubbe J. Generation of the R2 Subunit of Ribonucleotide Reductase by Intein Chemistry:  Insertion of 3-Nitrotyrosine at Residue 356 as a Probe of the Radical Initiation Process. Biochemistry. 2003;42: 14541–14552. doi: 10.1021/bi0352365 [DOI] [PubMed] [Google Scholar]
  • 52.Kang G, Taguchi AT, Stubbe J, Drennan CL. Structure of a trapped radical transfer pathway within a ribonucleotide reductase holocomplex. Science. 2020;368: 424–427. doi: 10.1126/science.aba6794 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Chen PY-T, Funk MA, Brignole EJ, Drennan CL. Disruption of an oligomeric interface prevents allosteric inhibition of Escherichia coli class Ia ribonucleotide reductase. J Biol Chem. 2018; jbc.RA118.002569. doi: 10.1074/jbc.RA118.002569 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Ge J, Yu G, Ator MA, Stubbe J. Pre-Steady-State and Steady-State Kinetic Analysis of E. coli Class I Ribonucleotide Reductase. Biochemistry. 2003;42: 10071–10083. doi: 10.1021/bi034374r [DOI] [PubMed] [Google Scholar]
  • 55.Gladyshev VN, Jeang KT, Stadtman TC. Selenocysteine, identified as the penultimate C-terminal residue in human T-cell thioredoxin reductase, corresponds to TGA in the human placental gene. Proc Natl Acad Sci U S A. 1996;93: 6146–6151. doi: 10.1073/pnas.93.12.6146 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Tamura T, Stadtman TC. A new selenoprotein from human lung adenocarcinoma cells: purification, properties, and thioredoxin reductase activity. Proc Natl Acad Sci U S A. 1996;93: 1006–1011. doi: 10.1073/pnas.93.3.1006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Darling AJ, Dutia BM, Marsden HS. Improved method for the measurement of ribonucleotide reductase activity. Journal of Virological Methods. 1987;18: 281–289. doi: 10.1016/0166-0934(87)90089-9 [DOI] [PubMed] [Google Scholar]
  • 58.Rofougaran R, Crona M, Vodnala M, Sjoberg B, Hofer A. Oligomerization status directs overall activity regulation of the Escherichia coli class Ia ribonucleotide reductase. The Journal of biological chemistry. 2008;283. doi: 10.1074/jbc.M806738200 [DOI] [PubMed] [Google Scholar]
  • 59.Grinberg IR, Lundin D, Hasan M, Crona M, Jonna VR, Loderer C, et al. Novel ATP-cone-driven allosteric regulation of ribonucleotide reductase via the radical-generating subunit. eLife Sciences. 2018;7: e31529. doi: 10.7554/eLife.31529 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Rehling D, Scaletti ER, Rozman Grinberg I, Lundin D, Sahlin M, Hofer A, et al. Structural and Biochemical Investigation of Class I Ribonucleotide Reductase from the Hyperthermophile Aquifex aeolicus. Biochemistry. 2022;61: 92–106. doi: 10.1021/acs.biochem.1c00503 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Rozman Grinberg I, Lundin D, Sahlin M, Crona M, Berggren G, Hofer A, et al. A glutaredoxin domain fused to the radical-generating subunit of ribonucleotide reductase (RNR) functions as an efficient RNR reductant. J Biol Chem. 2018. doi: 10.1074/jbc.RA118.004991 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Rozman Grinberg I, Berglund S, Hasan M, Lundin D, Ho FM, Magnuson A, et al. Class Id ribonucleotide reductase utilizes a Mn2(IV,III) cofactor and undergoes large conformational changes on metal loading. J Biol Inorg Chem. 2019. [cited 19 Aug 2019]. doi: 10.1007/s00775-019-01697-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Martínez-Carranza M, Jonna VR, Lundin D, Sahlin M, Carlson L-A, Jemal N, et al. A ribonucleotide reductase from Clostridium botulinum reveals distinct evolutionary pathways to regulation via the overall activity site. J Biol Chem. 2020; jbc.RA120.014895. doi: 10.1074/jbc.RA120.014895 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Atkin CL, Thelander L, Reichard P, Lang G. Iron and free radical in ribonucleotide reductase. Exchange of iron and Mössbauer spectroscopy of the protein B2 subunit of the Escherichia coli enzyme. J Biol Chem. 1973;248: 7464–7472. [PubMed] [Google Scholar]
  • 65.Thelander L, Gräslund A, Thelander M. Continual presence of oxygen and iron required for mammalian ribonucleotide reduction: Possible regulation mechanism. Biochemical and Biophysical Research Communications. 1983;110: 859–865. doi: 10.1016/0006-291x(83)91040-9 [DOI] [PubMed] [Google Scholar]
  • 66.van der Donk WA, Yu G, Silva DJ, Stubbe J, McCarthy JR, Jarvi ET, et al. Inactivation of Ribonucleotide Reductase by (E)-2‘-Fluoromethylene-2‘-deoxycytidine 5‘-Diphosphate:  A Paradigm for Nucleotide Mechanism-Based Inhibitors. Biochemistry. 1996;35: 8381–8391. doi: 10.1021/bi960190j [DOI] [PubMed] [Google Scholar]
  • 67.Lin Q, Parker MJ, Taguchi AT, Ravichandran K, Kim A, Kang G, et al. Glutamate 52-β at the α/β subunit interface of Escherichia coli class Ia ribonucleotide reductase is essential for conformational gating of radical transfer. J Biol Chem. 2017;292: 9229–9239. doi: 10.1074/jbc.M117.783092 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Ravichandran KR, Minnihan EC, Wei Y, Nocera DG, Stubbe J. Reverse Electron Transfer Completes the Catalytic Cycle in a 2,3,5-Trifluorotyrosine-Substituted Ribonucleotide Reductase. J Am Chem Soc. 2015;137: 14387–14395. doi: 10.1021/jacs.5b09189 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Birgander PL, Kasrayan A, Sjöberg B-M. Mutant R1 Proteins from Escherichia coli Class Ia Ribonucleotide Reductase with Altered Responses to dATP Inhibition. Journal of Biological Chemistry. 2004;279: 14496–14501. doi: 10.1074/jbc.M310142200 [DOI] [PubMed] [Google Scholar]
  • 70.Wei Y, Li B, Prakash D, Ferry JG, Elliott SJ, Stubbe J. A Ferredoxin Disulfide Reductase Delivers Electrons to the Methanosarcina barkeri Class III Ribonucleotide Reductase. Biochemistry. 2015;54: 7019–7028. doi: 10.1021/acs.biochem.5b01092 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Traut TW. Physiological concentrations of purines and pyrimidines. Mol Cell Biochem. 1994;140: 1–22. doi: 10.1007/BF00928361 [DOI] [PubMed] [Google Scholar]
  • 72.Buckstein MH, He J, Rubin H. Characterization of nucleotide pools as a function of physiological state in Escherichia coli. J Bacteriol. 2008;190: 718–726. doi: 10.1128/JB.01020-07 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Bochner BR, Ames BN. Complete analysis of cellular nucleotides by two-dimensional thin layer chromatography. J Biol Chem. 1982;257: 9759–9769. [PubMed] [Google Scholar]
  • 74.Minnihan EC, Seyedsayamdost MR, Uhlin U, Stubbe J. Kinetics of radical intermediate formation and deoxynucleotide production in 3-aminotyrosine-substituted Escherichia coli ribonucleotide reductases. J Am Chem Soc. 2011;133: 9430–9440. doi: 10.1021/ja201640n [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Backman LRF, Funk MA, Dawson CD, Drennan CatherineL. New tricks for the glycyl radical enzyme family. Crit Rev Biochem Mol Biol. 2017;52: 674–695. doi: 10.1080/10409238.2017.1373741 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Eliasson R, Pontis E, Sun X, Reichard P. Allosteric control of the substrate specificity of the anaerobic ribonucleotide reductase from Escherichia coli. J Biol Chem. 1994;269: 26052–26057. [PubMed] [Google Scholar]
  • 77.Larsson A, Reichard P. Allosteric effects and substrate specificity of the ribonucleoside diphosphate reductase system from Escherichia coli B. Biochim Biophys Acta. 1966;113: 407–408. doi: 10.1016/s0926-6593(66)80083-8 [DOI] [PubMed] [Google Scholar]
  • 78.Ando N, Brignole EJ, Zimanyi CM, Funk MA, Yokoyama K, Asturias FJ, et al. Structural interconversions modulate activity of Escherichia coli ribonucleotide reductase. PNAS. 2011;108: 21046–21051. doi: 10.1073/pnas.1112715108 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Holmgren A, Reichard P, Thelander L. Enzymatic synthesis of deoxyribonucleotides, 8. The effects of ATP and dATP in the CDP reductase system from E. coli. Proc Natl Acad Sci U S A. 1965;54: 830–836. doi: 10.1073/pnas.54.3.830 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Ravichandran K, Olshansky L, Nocera DG, Stubbe J. Subunit Interaction Dynamics of Class Ia Ribonucleotide Reductases: In Search of a Robust Assay. Biochemistry. 2020;59: 1442–1453. doi: 10.1021/acs.biochem.0c00001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81.Mao SS, Holler TP, Yu GX, Bollinger JM, Booker S, Johnston MI, et al. A model for the role of multiple cysteine residues involved in ribonucleotide reduction: amazing and still confusing. Biochemistry. 1992;31: 9733–9743. doi: 10.1021/bi00155a029 [DOI] [PubMed] [Google Scholar]
  • 82.Mao SS, Johnston MI, Bollinger JM, Stubbe J. Mechanism-based inhibition of a mutant Escherichia coli ribonucleotide reductase (cysteine-225—-serine) by its substrate CDP. PNAS. 1989;86: 1485–1489. doi: 10.1073/pnas.86.5.1485 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83.Levitz TS, Brignole EJ, Fong I, Darrow MC, Drennan CL. Effects of chameleon dispense-to-plunge speed on particle concentration, complex formation, and final resolution: A case study using the Neisseria gonorrhoeae ribonucleotide reductase inactive complex. Journal of Structural Biology. 2022;214: 107825. doi: 10.1016/j.jsb.2021.107825 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84.Gerstein AS. Nucleotides, Oligonucleotides,and Polynucleotides. Molecular Biology Problem Solver. John Wiley & Sons, Ltd; 2001. pp. 267–289. doi: 10.1002/0471223905.ch10 [DOI] [Google Scholar]
  • 85.Logan DT, Mulliez E, Larsson K-M, Bodevin S, Atta M, Garnaud PE, et al. A metal-binding site in the catalytic subunit of anaerobic ribonucleotide reductase. Proc Natl Acad Sci U S A. 2003;100: 3826–3831. doi: 10.1073/pnas.0736456100 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Anna Kristina Croft

Transfer Alert

This paper was transferred from another journal. As a result, its full editorial history (including decision letters, peer reviews and author responses) may not be present.

15 Mar 2022

PONE-D-22-03785A rapid and sensitive assay for quantifying the activity of both aerobic and anaerobic ribonucleotide reductases acting upon any or all substratesPLOS ONE

Dear Prof Drennan,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it both has merit and would benefit from addressing the comments of the reviewers to improve the manuscript prior to publication. Therefore, we invite you to submit a revised version of the manuscript with these points raised during the review process addressed. Specifically, reviewer 3 presents a number of points that we feel would help to clarify the manuscript and support wider uptake of the protocols outlined, alongside improvements suggested by the other reviewers (please see the attachments for details).

Please submit your revised manuscript by Apr 29 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Anna Kristina Croft

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf.

2. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. 

When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: I Don't Know

Reviewer #3: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Summary: Drennan et al. present a versatile assay for RNR activity. This assay has several benefits: it does not require radiolabeled nucleotide substrates and the associated infrastructure for working with and quantitating radioactive samples, it enables rapid and semi-high throughput product quantitation which in turn allows a wide variety of conditions to be screened, and it is applicable to a variety of RNRs from different classes and organisms. The conclusions are well-supported and are of broad interest to the readership of PLOS ONE. Suggestions to improve the clarity of the presented work are attached, but with these emendations, I strongly support publication. The initial assay results reported already reveal important new insights into RNR allostery.

Reviewer #2: The presented manuscript describes the development of an LC-MS/MS activity assay for the partial characterisation of ribonucleotide reductases (RNs) by making use of their intrinsic allosteric inhibition which determines the product distribution. Thus, this method can assay RNs conversion of ribonucleotides (substrates) in the presence of all four at the same time. Further, the method is faster and does not require handling of radioactive materials.

Overall, the manuscript is very well written and interesting to read. I am not an expert in the field but had overall no difficulties understanding it.

My only suggestion is a linguistic one – the meaning in line 347, I had to read a couple of times until I got the pieces together. Would it be possible changing “prior to use of heat” to “before using/applying heat”?

Recommend for publication as it stands.

Reviewer #3: Answers to questions above:

1. There are some assumptions and activity adjustments in the manuscript which are not specified.

4. There are more than one incomplete sentences.

Review uploaded as an attachment

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Martina Lahmann

Reviewer #3: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: PLOS_ONE_Drennan_rev.pdf

Attachment

Submitted filename: Reviewer comments PONE-D-22-03785.pdf

Decision Letter 1

Anna Kristina Croft

19 May 2022

PONE-D-22-03785R1A rapid and sensitive assay for quantifying the activity of both aerobic and anaerobic ribonucleotide reductases acting upon any or all substratesPLOS ONE

Dear Cathy,

Thank you for submitting your manuscript to PLOS ONE. 

==============================Only one minor point to address from the reviewer; please see review comments. 

==============================

Please submit your revised manuscript by Jul 03 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Anna Kristina Croft

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #3: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #3: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #3: The authors have responded satisfactorily to all questions, except for one point. It is still not clear from the determination of protein activity from LC-MS/MS data how the activity of E. coli NrdB is calculated. The radical content of EcNrdB was determined to 1.2 radicals per dimer, and the authors state in their response that “we believe that NrdB must have 2 radicals/dimer to be active”. Is the activity of 10 000 nmol dCDP/mg-min for EcNrdB adjusted for radical content or not? The question is valid, as the activity of S. thermophilus NrdD is adjusted for radical content. Whether the activity of EcNrdB has been adjusted for radical content or not needs to be clearly spelled out in the section on lines 252-266 where EcNrdB activity is reported or in the section on lines 855-864 where the adjustment of StNrdD activity is described.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #3: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Jun 8;17(6):e0269572. doi: 10.1371/journal.pone.0269572.r004

Author response to Decision Letter 1


22 May 2022

Response to one remaining reviewer comment

Reviewer #3: The authors have responded satisfactorily to all questions, except for one point. It is still not clear from the determination of protein activity from LC-MS/MS data how the activity of E. coli NrdB is calculated. The radical content of EcNrdB was determined to 1.2 radicals per dimer, and the authors state in their response that “we believe that NrdB must have 2 radicals/dimer to be active”. Is the activity of 10 000 nmol dCDP/mg-min for EcNrdB adjusted for radical content or not? The question is valid, as the activity of S. thermophilus NrdD is adjusted for radical content. Whether the activity of EcNrdB has been adjusted for radical content or not needs to be clearly spelled out in the section on lines 252-266 where EcNrdB activity is reported or in the section on lines 855-864 where the adjustment of StNrdD activity is described.

The activity of 10 000 nmol dCDP / mg-min for EcNrdB is not adjusted for radical content. We had added a sentence describing this in the same area of the methods where the adjustment is described for NrdD:

The slope was divided by the total mg of the limiting protein present in each 10 µL injection to yield nmoles/mg-min for each time course. For aerobic assays, limiting protein was total mg of either NrdA or NrdB (not adjusted for radical content); for anaerobic assays, limiting protein was total mg activated NrdD present, with total mg NrdD adjusted based on concentration of glycyl radical identified in EPR analysis assuming maximal radical concentration of 2 radicals per dimer.

Attachment

Submitted filename: Response to reviewers 2.docx

Decision Letter 2

Anna Kristina Croft

24 May 2022

A rapid and sensitive assay for quantifying the activity of both aerobic and anaerobic ribonucleotide reductases acting upon any or all substrates

PONE-D-22-03785R2

Dear Prof. Drennan,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Anna Kristina Croft

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Anna Kristina Croft

30 May 2022

PONE-D-22-03785R2

A rapid and sensitive assay for quantifying the activity of both aerobic and anaerobic ribonucleotide reductases acting upon any or all substrates

Dear Dr. Drennan:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Anna Kristina Croft

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. Time taken for water to reach various temperatures upon insertion into a 95°C thermocycler.

    Each temperature was assayed five times using 40 μL of water in a thin-walled PCR tube that had an initial temperature of 37°C.

    (DOCX)

    S2 Table. MRM parameters for each of the four deoxyribonucleoside products and their corresponding internal standards quantified in the RNR reaction.

    (DOCX)

    S3 Table. LC-MS program used for the LC-MS/MS experiments.

    (DOCX)

    S1 Fig. Protein melting peaks of StNrdD in different nucleotide conditions.

    Protein melting peaks of StNrdD with no nucleotides (StNrdD alone) or 1 mM TTP and GTP and either 3 mM ATP or 3 mM dATP. Table insert summarizes the melting temperature of StNrdD under the three conditions, which equates to the temperature at the negative peak of each curve.

    (TIF)

    S2 Fig. Optimization of dephosphorylation step using calf intestinal phosphatase (CIP).

    (A) Variation in dephosphorylation based on volume CIP added and incubation time (at 37°C) on a solution of 3 mM ATP and 1 mM CTP. Dephosphorylation was determined by adenosine MRM signal and was compared to a standard of 3 mM adenosine nucleoside. 1 μL CIP addition and incubation for 2 hours was used for all further studies. (B) Impact of the addition of CutSmart buffer to the CIP incubation mixture on a solution of 3 mM ATP and 1 mM CTP. Dephosphorylation was determined by cytidine MRM signal and was compared to a standard of 1 mM cytidine nucleoside. No CutSmart buffer was added in any further studies.

    (TIF)

    S3 Fig. Standard curve optimization.

    The presence of substrate and effector nucleosides and/or phosphates in addition to the measured deoxyribonucleoside standard is essential in generation of accurate standard curves. A comparison of dA, dC, dG, and dU standard curves generated either from deoxyribonucleotide triphosphates in the presence of substrates and effectors (navy), deoxyribonucleotide triphosphates but no substrates or effectors (purple), or only deoxyribonucleosides (no phosphates; light blue). For conditions where nucleotides were present, nucleotides were treated with CIP prior to analysis by mass spectrometry. Concentrations of substrate and effector nucleotides were as follows: ADP (110 μM), GDP (200 μM), UDP (50 μM), CDP (70 μM), ATP (3 mM). All products measured by LC-MS/MS ranged from 0–100 μM.

    (TIF)

    S4 Fig. TIC and MRM curves for the four ribonucleotide substrate experiment depicted in Fig 7.

    (A) TIC and MRM curves for each of the four standard curves. (B) TIC and MRM curves for the activity assay. The above condition contained Trx (30 μM), TrxR (0.5 μM), NADPH (200 μM), ATP (3000 μM), dATP (500 μM), TTP (250 μM), dGTP (100 μM), CDP (70 μM), UDP (50 μM), GDP (200 μM), ADP (110 μM), NrdA (0.1 μM dimer), and NrdB (0.5 μM dimer).

    (TIF)

    S5 Fig. Limits of detection of the four deoxynucleosides on the Agilent 6410 system.

    (A) Lower limit of detection for each of the four deoxynucleosides. (B) Standard curves are linear at up to 10 nmoles injected deoxyribonucleoside for each product. Note that the upper limit of detection and the upper linear range are both likely higher but are not anticipated to be relevant to RNR assays. Each data point is the mean ± standard error of the mean of three replicates.

    (TIF)

    S6 Fig

    EPR spectra of native (green) and reconstituted (blue) NrdB. EPR parameters were 80K, 10 scans, center field 3330 G, sweep width 300 G, sweep time 20 s, microwave power 38dB, modulation amplitude 1.5G. Double integrals were 134.5 and 580.6 for 100 μM native and reconstituted protein, respectively, leading to radical content of 0.3 and 1.2 radicals per dimer, respectively.

    (TIF)

    S7 Fig. EPR spectra of the glycyl radical in wild-type StNrdD.

    EPR parameters were 80K, 10 scans, modulation amplitude 3G, center field 3350 G, sweep width 200G, sweep time 21 s, microwave power 52dB.

    (TIF)

    Attachment

    Submitted filename: PLOS_ONE_Drennan_rev.pdf

    Attachment

    Submitted filename: Reviewer comments PONE-D-22-03785.pdf

    Attachment

    Submitted filename: Reviews_compiled_withresponses.pdf

    Attachment

    Submitted filename: Response to reviewers 2.docx

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting Information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES